CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner Committed Award Cash	Cumulative Funding
				(During CDC Fiscal Year 2016)	(All Years)
1	12/1/2012	3/31/2017	Acrylamide Exposure and Risk of Endometrial and Ovarian Cancer		
			To assess exposure to acrylamide in a subset of the European Prospective Investigation into Cancer and Nutrition (EPIC) study cohort and assess possible associations between acrylamide exposure and endometrial and ovarian cancers. Prior Years Funding Partner(s): Bellvitge Biomedical Research Institute		\$130,559.00
2	8/1/2002	6/30/2016	Active Living Research		
			To encourage transdisciplinary collaboration and build a research field that identifies environmental factors and public and private policies that have the potential to influence physical activity and sedentary behavior throughout the population of the United States. Prior Years Funding Partner(s): San Diego State University Research Foundation		\$192,937.00
3	12/1/2011	1/31/2017	Adaptation of Evidence-Based Interventions in Violence Prevention		
			To help CDC learn how evidence-based interventions to prevent violence currently are being implemented and adapted in the field and how to maximize adoption and use of evidence-based interventions successfully over time. Prior Years Funding Partner(s): Robert Wood Johnson Foundation		\$1,701,264.00
4	12/1/2013	ongoing	Addressing Health Disparities in the United States and Brazil		
			To examine racial disparities in health and develop a joint action plan between the United States and Brazil. The partnership facilitates cross-country collaboration by examining, disseminating and applying innovative approaches to reducing or eliminating racial discrimination in health for black populations. Prior Years Funding Partner(s): W.K. Kellogg Foundation		\$150,000.00
				Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	ring CDC Fiscal Year 2016)		(All Years)
							1
5	6/1/2015	12/31/2016	Adipose Deposition of Environmental Toxins				
			To determine which of the selected environmental chemicals detected in blood in the NHANES survey by CDC can be detected and measured in the serum and urine tissue, as well as the change over time in the detected environmental toxin levels in the blood and urine of patients who undergo bariatric surgery and experience significant weight loss. Prior Years Funding Partner(s): Johns Hopkins University				\$33,995.63
6	2/1/2011	7/31/2016	Aetiology of Neonatal Infection in South Asia				
			To characterize the pathogens that cause infections in young infants in developing countries - particularly Bangladesh, Pakistan and India - including a description of incidence, antimicrobial susceptibility and strain properties. Prior Years Funding Partner(s): Dhaka Shishu Hospital (International Centre for Diarrhoeal Disease Research)				\$1,734,048.00
7	9/1/2015	ongoing	AIDS and Kaposi's Sarcoma in Uganda				
			To perform Human Herpesvirus-8 (HHV-8) diagnostics on specimens from a UCSF study on antiretroviral therapy for patients with AIDS and Kaposi's sarcoma in Uganda. Prior Years Funding Partner(s): University of California, San Francisco				\$30,000.00
8	6/1/2014	12/31/2016	Alternative Sanitation in Protracted Emergencies				
			To determine the safety and acceptability of urine-diversion toilets (UDTs) in refugee camps in Ethiopia in order to provide guidance on their use in humanitarian crises. By determining the environmental conditions necessary for maximum pathogen removal in a real setting, this will help improve existing and future UDT programs. Prior Years Funding Partner(s): Enhancing Learning and Research for Humanitarian Assistance	Enhancing Learning and Research for Humanitarian Assistance		\$135,800.06	\$264,729.67
						Revise	d: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
9	8/1/2014	7/31/2016	Analysis of the Global Burden of Norovirus				40
			To implement a landscape analysis and hold a consultative meeting focused on gathering current data on the global burden of norovirus disease and the epidemiology of norovirus infections. The outcome will include a white paper on the current burden of norovirus and vaccine prospects				\$214,935.00
			Prior Years Funding Partner(s):				
			Bill & Melinda Gates Foundation				
10	10/1/2014	12/31/2016	Antimicrobial Chemicals in Allergic Disease				
			To investigate whether exposure to the antimicrobial phenols (e.g., triclosan and parabens) increases the risk of developing allergen sensitization and clinical allergic disease via inducing dysbiosis of the human microbiota.				\$164,268.00
			Prior Years Funding Partner(s):				
			Partners HealthCare System, Inc. (Harvard University)				
11	7/1/2011	3/1/2016	Antimicrobial Stewardship Programs				
			To demonstrate the efficacy of an anti-microbial stewardship project in long-term care facilities using the syndromic approach targeting urinary tract infections.				\$71,043.00
			Prior Years Funding Partner(s):				
			Merck & Co., Inc.				
12	5/1/2015	5/31/2020	Antimicrobials: The Microbiome and Gene Expression				
			To perform interventional trials on the use of triclosan and non-triclosan containing products and determine the effects of triclosan use on the microbiome and on gene expression.				\$23,244.80
			Prior Years Funding Partner(s):				
			Partners HealthCare System, Inc.				
			(Harvard University)				
				1			1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
13	7/1/2015	9/30/2016	Assessment of Nanoparticle Toxicity				
			To systematically study the mechanisms of in vivo breakdown and processing of inhaled nanomaterials.				\$10,000.00
			Prior Years Funding Partner(s): University of Kentucky				
14	7/1/2016	7/30/2018	Assessment of Occupational Fall Hazards				
			To improve worker safety while using mast climbing work platforms (MCWP).	Job-Site Safety Institute	\$40,600.00		\$40,600.00
15	3/1/2011	3/1/2016	Asthma and Secondhand Smoking				
			To quantify exposure to secondhand smoke by measuring levels of nicotine metabolites and then assess the relationship between secondhand smoke exposure and the development of asthma and allergey in children. Prior Years Funding Partner(s):				\$220,800.00
			Simon Fraser University				
16	6/1/2006	ongoing	Bed Nets for Children				
		J J	To prevent the spread of malaria by distributing insecticide-treated bed nets to pregnant women and children in Africa who are most at risk for contracting and dying from malaria.	Various Individual and Organizational Contributors		\$4,314.27	\$145,437.75
			Prior Years Funding Partner(s):				
			Clarence E. Heller Charitable Foundation				
			Various Individual and Organizational Contributors				
17	11/1/2012	8/31/2016	Biomarker Detection of Cervical Cancer				
			To help CDC participate in research to evaluate the use of the magnetic microfluidic chip to improve detection of cervical cancer.				\$123,099.30
			Prior Years Funding Partner(s): The University of Georgia				
				1		Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
18	9/1/2013	3/31/2016	Biomarkers of Infertility				
			To study biomarkers of infertility in 750 women trying to conceive over 12 months. CDC will perform a sample analysis and advise on the study design, sample collection and data analyses, measuring FSH and the estrogen metabolite, estrone 3-glucuronide, for standardized pregnancy determination.				\$14,871.00
			Prior Years Funding Partner(s):				
			University of North Carolina at Chapel Hill				
19	12/1/2009	8/30/2016	Birth-cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C)				
			To support Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C), a multi-year study that will evaluate the effectiveness of screening all persons born between 1945 and 1964 for HCV in order to increase the proportion of people who are aware of their HCV status. Prior Years Funding Partner(s): AbbVie Inc. Genentech, Inc. Johnson & Johnson Pharmaceutical Services, LLC Merck Sharp & Dohme Corp. Vertex Pharmaceuticals, Incorporated				\$3,928,000.00
20	8/1/2015	3/31/2016	Bisphenol A Exposure and Gestational Diabetes				
			To measure urinary concentrations of environmental phenols to assess whether exposure to environmental chemicals such as Bisphenol A is associated with an increased risk of Gestational Diabetes. Prior Years Funding Partner(s): University of Cincinnati	S			\$17,300.40
						Revise	ed: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					During CDC Fiscal Year 2016)		(All Years)
21	7/1/2013	ongoing	BPA Exposure and Risk for Obesity and Diabetes				
			To monitor the prospective association of bisphenol A (BPA) exposure with risk for obesity and diabetes. Additionally, the role of epigenetic factors in mediating the association between BPA exposure and risk for obesity and diabetes will be investigated. A pilot study will use preliminary data from 170 samples collected for the Emory Twins Study between 2001 and 2010.				\$58,890.00
			Prior Years Funding Partner(s):				
			Tulane University				
			University of Oklahoma Health Sciences Center				
22	5/1/2013	12/31/2015	Building Networks for Health Equity				
23	12/1/2015	12/31/2016	The Breakthrough Initiative is a collaborative effort between the National Association of County and City Health Officials (NACCHO), the Healthy Heartlands Coalition of faith-based community organizations and CDC's Division of Violence Prevention. The Breakthrough Initiative is designed to intervene on inequities in health and safety through the development of networks and collaborative actions between local public health agencies and faith-based community organizations. Prior Years Funding Partner(s): W.K. Kellogg Foundation Caffeine Consumption Validation Study				\$200,000.02
	, _,	,		11 to 20 CW to 1	A7 200 00		AT 200 00
			To investigate the validity of a 24-hour caffeine recall survey.	University of Waterloo	\$7,308.00		\$7,308.00
24	3/1/2012	7/31/2016	Candidemia Surveillance and C. Glabrata				
	-, -,	,,,	To help CDC advance the study of the effects of certain genetic mutations of candida glabrata (C. glabata) on the effectiveness of antifungal treatments. Candida species are the third leading cause of healthcare-associated bloodstream infections, and CDC is the only entity in the U.S. conducting active population-based surveillance for these infections. Prior Years Funding Partner(s): Astellas Pharma US, Inc.				\$15,720.00
						Revised: 1	1142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				1)	During CDC Fiscal Year 2016)		(All Years)
25	5/1/2016	6/30/2017	Cardiovascular and Carcinogenic Risks in Training Scenarios				
			To conduct a study to assess firefighters' cardiovascular and carcinogenic risks during training scenarios.	University of Illinois		\$200,000.00	\$200,000.00
26	7/17/2007	7/31/2016	CDC Experience Legacy Project				
			To enhance development of health professionals by providing them tools to expand their competency in community and population-based health.				\$2,840,598.00
			Prior Years Funding Partner(s): Pfizer Inc.				
27	5/1/2007	12/30/2015	Central Asia Blood System Evaluation				
			To evaluate the blood donor recruitment system, the quality of laboratory screening procedures for blood donations, and the current guidelines for the clinical use of blood components in four countries in central Asia. To identify gaps in blood services, make recommendations to address those gaps, and then implement and evaluate proposed interventions in the problem areas.				\$85,000.00
			Prior Years Funding Partner(s):				
			International Bank for Reconstruction and Development				
28	12/1/2015	12/31/2016	Certified Water Quality Laboratory in Kenya				
			To make improvements to a water laboratory in Kenya that will enable it to be certified by the Ministry of Health. A certified laboratory would be authorized to become a regional reference laboratory that would provide needed services in the region such as water quality monitoring, outbreak response and research support.	Proctor & Gamble Company		\$28,878.00	\$28,878.00
29	10/9/2013	12/31/2016	CHAMACOS Environmental Study				
			To examine the association of exposure to phthalates with health outcomes in child development using samples collected from participants of the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) study. CDC's Organic Analytical Toxicology Branch will measure the urinary concentrations of phthalate metabolites in urine collected from CHAMACOS participants. Approximately 700 samples will be analyzed for phthalate metabolites. Prior Years Funding Partner(s): University of California, Berkeley				\$76,830.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Dur	ring CDC Fiscal Year 2016)		(All Years)
30	8/1/2016	8/30/2020	Chemicals and Exosomal miRNAs in Ovarian Follicles				
			To evaluate the association between exposure to endocrine disputing chemicals and fertility by measuring microRNA (miRNA) profiles in follicular fluid isolated exosomes with oocyte maturation and day three embryo quality.	Harvard University	\$289,290.00		\$289,290.00
31	2/1/2012	12/31/2016	Child Development and Exposure to Phthalates and BPA				
			To assess the effects of exposure to phthalates and bisphenol A (BPA) on the fetal and pubertal development of children. Prior Years Funding Partner(s):	University of Illinois at Urbana-Champaign	\$55,900.00		\$181,329.28
			Partners Healthcare System, Inc. (Harvard Medical School)				
			University of Illinois at Urbana-Champaign				
			omersity or minor at organic onempage.				
32	11/5/2013	9/30/2016	Childhood Autism from Genetics and the Environment				
			To compare the cognitive and adaptive functions of children with autism to normally developing and mentally retarded children and to evaluate the connection between high gestational folic acid levels and reduced risk for autism. CDC's Division of Laboratory Sciences Nutritional Biomarkers Branch will measure 851 newborn dried blood spot samples from the State of California's newborn screening bank in the "CHARGE" study, Childhood Autism Risks from Genetics and the Environment.				\$40,759.68
			Prior Years Funding Partner(s):				
			University of California, Davis				
33	12/1/2015	Ongoing	Childhood Immunization Champions				
			To recognize individuals in each U.S. state who make a significant contribution toward improving public health through their work in childhood immunization.	Various Individual Contributors		\$6,500.00	\$6,500.00
34	6/1/2013	1/31/2016	China Tobacco Questions for Surveys (TQS) Cities Project				
			To conduct stand-alone Tobacco Questions for Surveys (TQS) in three Chinese cities. Prior Years Funding Partner(s):				\$113,000.00
			Emory University				
				I		1	Revised: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
35	10/1/2015	9/30/2017	500 Cities Project				
			To promote chronic disease prevention and health promotion for the 500 largest American cities by identifying, analyzing and reporting census tract-level data through an interactive City Health Indicator website.	Robert Wood Johnson Foundation	\$874,720.00		\$874,720.00
36	8/1/2015	7/30/2020	Chronic Hepatitis B Virus Infection in Tanzania				
			To implement and evaluate the feasibility of a care and treatment model for persons infected with chronic hepatitis B virus in resource-limited settings.				\$439,252.74
İ			Prior Years Funding Partner(s):				
			Gilead Sciences, Inc.				
37	1/1/2014	12/31/2016	Chronic Kidney Disease in Central American Workers				
			To investigate potential occupational causes of Chronic Kidney Disease in Central American countries. Prior Years Funding Partner(s):				\$1,050,000.00
			Association of Sugar Producers in Honduras				
			Comité Nacional de Productores de Azúcar				
			Liga Agricola Ind Cana de Azucar				
			Los Azucareros del Istmo Centroamericano				
			Sugar Association of Guatemala				
			Sugar Association of El Salvador				
38	2/1/2009	9/30/2016	Chronic Viral Hepatitis B and C Cohort Study (CHeCS)				
			To establish the first comprehensive U.S. longitudinal observational cohort of 15,000 or more patients with chronic viral hepatitis B and C in order to improve understanding of chronic viral hepatitis and the impact of screening, care and treatment recommendations.				\$10,350,000.00
			Prior Years Funding Partner(s):				'
			Abbott Laboratories				
			AbbVie Inc.				
			Bristol-Myers Squibb Company				
			Genentech, Inc.	I		Paviand	111.4004.0
i						Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	ring CDC Fiscal Year 2016)		(All Years)
			Gilead Sciences, Inc. Janssen Global Services, LLC Johnson & Johnson Pharmaceutical Services, LLC Vertex Pharmaceuticals, Incorporated				
39	3/1/2016	7/31/2018	Cleaning Procedures for Fire Fighter PPE				
			To establish clear guidance for applying cleaning and decontamination procedures that effectively remove both chemical and biological contaminants from fire fighter personal protective equipment (PPE).	The Fire Protection Research Foundation	\$412,104.00		\$412,104.00
40	3/1/2014	11/30/2017	Clinical Trials Unit for HIV/AIDS and TB Research				
			To facilitate formation of a Clinical Trials Unit for HIV/AIDS and tuberculosis research to advance therapy and prevention. If the interventions in the clinical trials are determined safe and effective, they will add to the options available to prevent and control these diseases of global significance. Prior Years Funding Partner(s): Emory University	Emory University	\$265,202.00		\$795,606.00
41	3/1/2016	6/30/2016	Combination HIV Prevention Intervention in Thailand				
			To conduct a study to assess the feasibility of a combination HIV preventive intervention with and without daily Truvada PrEP for HIV uninfected young men who have sex with men in Bangkok, Thailand.	Johns Hopkins University	\$518,272.00		\$518,272.00
42	4/1/2013	12/30/2015	Communicating the Value of Public Health				
			To increase private-sector understanding of CDC's role in population-based health and to build public-private partnerships that advance public health priorities. This funding will support an initiative to highlight the value of CDC as the nation's leading health protection agency. The desired goal is greater private-sector appreciation for CDC and public health. Prior Years Funding Partner(s):				\$1,000,000.00
			The Robert W. Woodruff Foundation, Inc.				
			The Reserve W. Woodi and Foundation, inc.			Revised: 1	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative Funding
			Prior Years Funding Partner(s):				. anamg
				(D	uring CDC Fiscal Year 2016)		(All Years)
				1			1
43	1/1/2010	3/31/2016	Consumer Education and Assisted Reproductive Technology				
	,,	.,.,	To create educational videos to help infertility patients make informed treatment decisions.				\$23,608.00
			Prior Years Funding Partner(s):				
			Aetna, Inc.				
44	6/1/2016	8/31/2018	Contraceptive Use Module for States				
			To support state use of a module on the Behavioral Risk Factor Surveillance System that assesses contraceptive use among women aged 50 and younger. This effort will allow for the development of state-level estimates of the methods of contraception used and reasons for not using contraception.	Guttmacher Institute		\$1,308,959.47	\$1,308,959.47
45	1/1/2015	7/31/2016	Controlling Mosquito Vectors of Malaria				
			To develop data that will contribute to an assessment of whether transgenic mosquitoes could be effectively and safely deployed to control natural populations of malaria vectors. Prior Years Funding Partner(s): Imperial College London	Imperial College London	\$327,624.00		\$843,209.00
46	9/1/2011	5/31/2016	Controlling Viral Foodborne Disease				
			To help CDC collaborate with the U.S. Department of Agriculture and the National Institute of Food and Agriculture to create an integrated, multi-disciplinary approach to developing improved tools, skills and capacity to study foodborne viruses, using these to systematically identify risk factors and develop risk management strategies to reduce contamination in pre- and post-harvest environments. Prior Years Funding Partner(s): North Carolina State University	North Carolina State University	\$809,606.00		\$2,014,124.00
47	10/1/2010	12/31/2016	Crimean-Congo Hemorrhagic Fever Study				
47	10, 1, 2010	12/31/2010	To research the nairovirus, Crimean-Congo hemorrhagic fever, a tick-borne viral disease, especially common in East and West Africa. With mortality rates as high as 80 percent and with no FDA approved vaccines or therapeutics, Crimean-Congo hemorrhagic fever is considered a	The University of Georgia	\$110,641.00	Revised: 1	\$343,315.82

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award (During CDC Fiscal Year 2016)	Cash	Cumulative Funding (All Years)
			dangerous pathogen and a serious bioterrorism threat. The project will expand the knowledge of the ovarian tumor protease domain of the nairovirus to inform control measures and vaccine development. Prior Years Funding Partner(s): European Commission Smittskyddsinstitutet The University of Georgia				
48	11/1/2014	3/30/2017	Cryptococcal Meningitis Screening in South Africa To provide technical assistance to the monitoring and evaluation of a cryptococcal screening program in partnership with the South African government. Cryptococcal meningitis is a common infection and a leading cause of death among individuals with HIV/AIDS. Prior Years Funding Partner(s): Pfizer Inc.				\$582,320.00
49	4/1/2015	8/31/2016	Data Collection System for Sickle Cell Disease To build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care, and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life. Prior Years Funding Partner(s): Biogen Idec Pfizer Inc.	Pfizer Inc	\$350,000.00		\$926,500.00
50	3/1/2015	3/31/2017	Data for Health To assist 20 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions. Prior Years Funding Partner(s): Bloomberg Philanthropies			Revised: 1	\$16,705,000.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative Funding
			Prior Years Funding Partner(s):	(D	Ouring CDC Fiscal Year 2016)		(All Years)
51	10/7/2013	12/31/2016	Data to Action and Monitoring Tobacco Use in Asia				
31	10/1/2013	12,31,2010	Work with other Bloomberg Initiative partners to reduce global tobacco use through surveillance and monitoring activities.				\$1,750,000.00
			Prior Years Funding Partner(s):				
			Bloomberg Philanthropies				
52	10/1/2003	ongoing	David J. Sencer CDC Museum				
			The David J. Sencer CDC Museum (formerly known as the Global Health Odyssey) serves as CDC's gateway to the public, and is dedicated to comprehensive scientific learning and outreach. Composed of permanent exhibits representing the breadth of CDC's work and history, topical changing exhibits, a theater and a classroom, this facility serves to educate all who visit about public health and the important work of CDC, with a special emphasis on curriculum-based educational workshops and camps targeting middle- and high-school students. Prior Years Funding Partner(s): Accenture Association of State & Territorial CDC Federal Credit Union Grantmakers In Health Pfizer Inc. The Florence C. & Harry L. English Memorial Fund The Harriet McDaniel Marshall Trust The John and Mary Franklin Foundation The Morris Family Foundation, Inc. The Thomas Guy Woolford Charitable Trust The Walter H. & Marjory M. Rich Memorial Fund Vestergaard Frandsen SA Various Individual and Organizational Contributors				\$231,011.50
53	7/1/2002	ongoing	David J. Sencer EIS Conference Scholarship Fund				
			To provide travel scholarships to qualified potential applicants to the EIS program to attend the annual EIS Conference in Atlanta, Georgia.	Various Individual and Organizational Contributors		\$3,940.00 Revised: 1	\$48,659.42

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(During CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): Various Individual and Organizational Contributors				
54	10/1/2015	ongoing	David J. Sencer Museum AIDS History Project				
			To document CDC's role during the early years of the AIDS epidemic by gathering information and documents from CDC scientists, public health advisors and other staff who worked during the early years of the epidemic.	Abbott Laboratories Gilead Sciences, Inc.	\$10,000.00 \$300,000.00		\$310,000.00
55	12/1/2015	12/30/2016	Development and Review of Logic Models				
			To enhance the quality of logic models used in program evaluation via a comprehensive checklist to guide development or review of logic models available at no-cost to users.	The Faster Forward Fund		\$3,850.00	\$3,850.00
56	8/1/2009	8/30/2016	Development of Inactivated Polio Vaccine Strains				
			To develop a genetically stable inactivated poliovirus vaccine. Prior Years Funding Partner(s): World Health Organization				\$500,000.00
57	10/1/2013	5/31/2017	Microbicide to Prevent HIV Transmission				
			To support the development of a safe and effective dual compartment microbicide to be applied either vaginally or rectally as pre-exposure prophylaxis (PrEP) against the transmission of HIV. Prior Years Funding Partner(s): ImQuest BioSciences	ImQuest Biosciences	\$189,121.00		\$363,764.00
58	5/1/2013	8/31/2016	Early Childhood Inequities Awareness Campaign				
			To support the dissemination of The Raising of America, a documentary series and multimedia initiative that reframes the way we look at early child health and development. This two-year national public engagement and education initiative aims to prevent child maltreatment and achieve health equity by improving social and economic conditions for all children and their families. Prior Years Funding Partner(s): Doris Duke Charitable Foundation			Revised:	\$150,000.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
					,		,
59	10/1/2008	1/31/2016	Early Childhood Mortality Collaboration				
39	10/1/2008	1/31/2010	To help CDC's Newborn Screening Branch collaborate with California's newborn screening				\$12,000.00
			program through the ongoing Early Childhood Mortality Collaborative Project.				\$12,000.00
			Prior Years Funding Partner(s):				
			The Evanosky Foundation				
60	8/1/2015	4/30/2016	Effects of Carcinogens from High Fat Diets				
			The purpose of this study is to investigate in a mouse model the potential effect of exposure to BP-3 on susceptibility to mammary tumor development and interaction with a diet high in animal fat.			·	\$6,973.44
			Prior Years Funding Partner(s): Michigan State University				
61	2/1/2016	5/31/2018	Effects of Chemicals on Child Development				
			To explore the potential impact during gestation of maternal exposure to personal care products (PCP) on physical and neurological developmental characteristics of the infants during their first years of life.	University of Illinois	\$305,275.05		\$305,275.05
62	4/1/2016	9/30/2017	Effects of Organic Diet on Pesticides Exposure				
			To evaluate the effects of maternal organic diet on exposure to pesticides during pregnancy.	Boise State University	\$18,164.00		\$18,164.00
63	5/1/2015	5/31/2020	Effects of Perfluoroalkyls on Stroke and Mortality				
			To investigate the association between exposure to polyfluorinated chemicals (PFCs) and the risk of stroke, as an ancillary project of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.				\$380,700.00
			Prior Years Funding Partner(s): West Virginia University				
				I		Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
64	12/1/2014	12/31/2016	Electronic Health Records For Hepatitis C Testing				
			To develop clinical quality improvement infrastructure for Hepatitis C screening and referral to treatment.				\$116,000.00
			Prior Years Funding Partner(s): Gilead Sciences, Inc.				
65	7/1/2010	1/31/2016	Emergency Obstetric Care in Tanzania				
			To improve access to quality emergency obstetric care and reduce maternal deaths in four pilot regions of Tanzania. Prior Years Funding Partner(s):				\$2,238,905.00
			Bloomberg Philanthropies				
66	12/1/2013	Ongoing	Emerging Infectious Disease				
			In support of global health and infectious disease programs. Prior Years Funding Partner(s): Various Individual and Organizational Contributors				\$2,953.53
67	2/1/2011	10/1/2016	Emerging Infectious Diseases in China				
			To enable a Pfizer Global health fellow to work alongside CDC scientist on assignment in China to improve prevention, detection and control of emerging infectious diseases. Prior Years Funding Partner(s): Pfizer Inc.				\$99,858.00
68	1/1/2011	ongoing	Emerging Infectious Diseases in China (China/Pfizer Global Health Fellows)				
			To enable a Pfizer Global Health Fellow to work alongside CDC scientists on assignment in China to improve prevention, detection and control of emerging infectious diseases. Prior Years Funding Partner(s): Pfizer Inc.				\$49,963.00
I				•		Revised:	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

			(October 1, 2013 - September 30, 2010)		
CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award During CDC Fiscal Year 2016)	Cash

			1 31131118 1 311 311 31		
Date	End Date	Program Description Prior Years Funding Partner(s):			Funding
			(D	uring CDC Fiscal Year 2016)	(All Years)
			·	·	, ,
69 5/1/2008	ongoing	Endocrine Disruptors and the Male Reproductive System			
		To study the influence of prenatal exposure to phthalates and bisphenol A (BPA) on the occurrence of genital abnormalities, specifically cryptorchidism and hypospadias, in the French general population.			\$166,252.98
		Prior Years Funding Partner(s):			
		INSERM			
70 5/1/2014	12/31/2018	Endocrine Disruptors and Uterine Fibroids			
		To evaluate exposure to phthalates, polychlorinated biphenyls (PCB), and bisphenol A (BPA) in relation to incident uterine leiomyomata (UL) in an established cohort of women from Study of Environment Lifestyle and Fibroids (SELF).	Boston University	\$875,012.00	\$875,012.00
71 9/1/2015	11/30/2017	Endocrine Disruptors Exposure and Prenatal Risk			
		To examine whether maternal exposure to endocrine disrupting chemicals such as phenols and phthalates affect the maternal ribonucleic acid profile as well as ribonucleic acid, proteins and hormonal levels. The study will determine whether in-utero and early life outcomes differ between male and female twins in the same twin pair. Prior Years Funding Partner(s): The Chaim Sheba Medical Center	Chaim Sheba Medical Center		\$0.00
72 3/1/2015	12/31/2017	Endocrine Disruptors: Prenatal Epigenetics			
		To investigate the potential association between prenatal exposure to endocrine disruptors and the development of adiposity-related outcomes in the offspring.	University of Colorado	\$270,806.00	\$270,806.00
73 10/1/2010	1/31/2017	Environmental Exposure and ALS			
		To measure the levels of gamma-tocopherols, 25-hydroxyvitamine, pesticides and blood lead and study their association with the development of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). Prior Years Funding Partner(s): Emory University			\$34,138.00
					I

Cumulative

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description				Funding
			Prior Years Funding Partner(s):				
					: cpc =: \		(AUN)
				(Dui	ring CDC Fiscal Year 2016)		(All Years)
7.4	2/1/2015	0/20/2016	Fusion Dialo in Madam Finsiina				
74	3/1/2015	9/30/2016	Evaluating Risks in Modern Firefighting To collaborate with the Illinois Fire Service Institute (IFSI) to conduct a study to assess firefighters'				\$165,000.00
			cardiovascular and carcinogenic risks during modern firefighting. IFSI will oversee each training				\$103,000.00
			scenario and collect a variety of measurements to assess firefighters' heat stress, physical exertion				
			and physiological strain. CDC's NIOSH will conduct external and internal exposure monitoring,				
			assess firefighter gear contamination, conduct data analysis and disseminate the results.				
			Prior Years Funding Partner(s):				
			University of Illinois				
75	1/1/2007	ongoing	Evaluating SafeWater Interventions				
73	1/1/2007	Oligonia	To support CDC's work with international partners to develop and evaluate new tools and				\$1,439,230.68
			strategies to improve access to safe drinking water at a household level.				\$1,433,230.00
			Prior Years Funding Partner(s):				
			The Clorox Company				
			The Greater Cincinnati Foundation				
			Procter & Gamble Company				
			Vestergaard Frandsen SA				
76	1/1/2015	12/31/2016	Evaluation of Cerus INTERCEPT System for Ebola				
			To evaluate the safety of Cerus Corporation's Intercept Platform's ability to inactivate the Ebola	Bill & Melinda Gates Foundation	\$94,611.00		\$94,611.00
			virus in human plasma.				
77	7/1/2007	7/31/2017	Evaluation of Malaria Specimen Bank				
**	77172007	7/31/2017	To analyze blood samples to determine what species of human malaria parasites are present in	Foundation for Innovative New Diagnostics	\$512,718.54		\$2,661,335.94
			the specimens as part of an evaluation of a global malaria specimen bank.	roundation for innovative New Bidgitosties	Ų312,710.34		72,001,333.54
			Prior Years Funding Partner(s):				
			Foundation for Innovative New Diagnostics				
70	2/4/2012	7/24/2047	Free book's an of Day was a balance of DD AAAC				
78	2/1/2012	7/31/2017	Evaluation of Program Impact through PRAMS To facilitate a collaboration between CDC and the W.K. Kellaga Foundation to access the national section.				62 474 007 00
			To facilitate a collaboration between CDC and the W.K. Kellogg Foundation to assess the potential impact of Kellogg-supported interventions through the use of CDC's Pregnancy Risk Assessment				\$2,474,907.00
			impact of Kellogg-supported interventions through the use of CDC's Freghancy Kisk Assessment				
				I			
						Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Monitoring System (PRAMS). PRAMS collects state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. Prior Years Funding Partner(s): W.K. Kellogg Foundation				
79	3/1/2016	3/31/2016	Evaluation of Rabies Virus Vectored Ebola Vaccine To design and evaluate a thermostable Rabies Virus Vectored Ebola Vaccine. As Ebola exists in some of the poorest parts of the world where the climate is tropical, the development of a thermostable vaccine could be cost-effective, resulting in greater long-term vaccine stability in high ambient temperatures.	Thomas Jefferson University	\$84,811.00		\$84,811.00
80	4/1/2016	3/30/2020	Evaluation of Rotavirus Vaccine in Vietnam To establish rotavirus surveillance, implement rotavirus vaccination introduction and evaluate	Bill & Melinda Gates Foundation	\$999,918.00		\$999,918.00
			impact and effectiveness of rotavirus vaccination in targeted districts in Vietnam.	Bill & Welliua Gates i Guildation	\$333,310.00		\$555,510. 00
81	4/1/2013	ongoing	Evaluation of UPS's Road Code Teen Driving Program				
			To conduct a program analysis and evaluation of United Parcel Service's (UPS) Road Code, an interactive program that brings UPS's safe driving techniques and methods to teenage drivers. CDC will conduct an analysis of the UPS Road Code curriculum, provide recommendations and resources based on the most recent and best available science and provide in-depth consultation on and assistance with the evaluation of the UPS Road Code program. Prior Years Funding Partner(s): The UPS Foundation, Inc.	The UPS Foundation, Inc.		\$100,000.00	\$303,565.00
82	6/1/2014	2/29/2016	Expanding Community Participation in SaludBoricua				
			To promote community participation in SaludBoricua, the Puerto Rico participatory surveillance program for acute febrile illnesses, which include dengue, influenza, leptospirosis and chikungunya. A mobile app will be developed to capture data and a media campaign launched to encourage participation. Prior Years Funding Partner(s): Skoll Global Threats Fund				\$91,000.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
0.3	11 /1 /2014	11/20/2016	Funda disa the James minetics Date Content in Niconia				
83	11/1/2014	11/30/2016	Expanding the Immunization Data System in Nigeria To overhaul the immunization data system at the National Health Care Development Agency of Nigeria. Expanding the information system will improve the accountability of the routine immunization program and provide the data for strategic planning and program implementation in Nigeria. Prior Years Funding Partner(s):				\$6,303,662.00
			Bill & Melinda Gates Foundation				
84	7/1/2015	12/31/2016	Exposure to Antibacterial Compounds				
			To examine whether exposure to certain antibacterial chemicals is implicated in allergic and respiratory diseases through alteration of the human microbiome. Prior Years Funding Partner(s):				\$76,842.61
			University of Bergen				
85	1/1/2012	12/30/2016	Exposure to Endocrine Disruptors and Breast Cancer Risk				
			To measure phthalate metabolites and phenols to help determine their potential role in breast cancer development. Prior Years Funding Partner(s): Mount Sinai School of Medicine				\$143,276.00
86	10/1/2013	12/31/2016	Family Planning Project in Tanzania				
			To increase access to comprehensive emergency obstetric care in Tanzania by integrating family planning into health centers. Prior Years Funding Partner(s): Bloomberg Philanthropies				\$1,500,000.00
87	1/1/2015	12/31/2017	Fibroids Research on Genes and Environment				
			To evaluate the role of environmental exposures by race/ethnicity, and to investigate the potential association between exposure to environmental chemicals and the risk of developing uterine leiomyomas.				\$22,679.32
						Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): The George Washington University (Milken Institute)				
88	1/1/2009	11/30/2016	Field Epidemiology Training Program - Saudi Arabia				
			To evaluate Saudi Arabia's infectious disease surveillance system, help train local and regional disease detectives and improve the country's capacity to monitor for and respond to infectious disease outbreaks. Prior Years Funding Partner(s): Kingdom of Saudi Arabia Ministry of Health				\$4,996,040.43
89	3/1/2013	Ongoing	Firearms-Related Violence Prevention Advisory Committee Research Agenda				
			To develop a research agenda to address the causes and prevention of gun violence. To meet this goal, CDC is requesting the Institute of Medicine, through the National Academy of Sciences (NAS) and in collaboration with the National Research Council, to appoint an advisory committee to develop the proposed research agenda, using established NAS procedures. The proposed agenda will identify the most critical research questions that can be answered in the short-term (3-5 years) to improve knowledge of the following: 1) causes of gun violence; 2) interventions that prevent gun violence; and 3) strategies to minimize the public health burden of gun violence. Prior Years Funding Partner(s): The Annie E. Casey Foundation The California Endowment The California Wellness Foundation GE Foundation The Joyce Foundation Kaiser Permanente Robert Wood Johnson Foundation				\$490,111.00
90	6/1/2015	3/31/2016	Flame Retardants and Flight Attendant Health				
			To assess the exposure to flame retardants and polyfluorinated compounds (PFCs) in flight attendants and evaluate the association between serum levels of flame retardants and PFCs and thyroid hormone disruption. Prior Years Funding Partner(s): Harvard University				\$11,479.18
						Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	Ouring CDC Fiscal Year 2016)		(All Years)
				()	ag = 2 - 135a. 1 - 2a. 20 - 20,		(/ iii / Gui o)
				I			1
91	6/1/2012	3/31/2017	Folate Status in the U.K. Population				
			To determine folate status across the U.K. in order to establish a population baseline should mandatory folic acid fortification proceed.	MRC Human Nutrition Research	\$360,000.44		\$692,527.97
			Prior Years Funding Partner(s):				
			MRC Human Nutrition Research				
				_			
92	2/1/2005	6/30/2016	Food Fortification Initiative				
			To promote the use of foods fortified with iron, zinc, calcium and folate around the world by	Australian Department of Foreign Affairs and Tr	rade	\$62,912.57	\$4,464,705.78
			encouraging the production and marketing of fortified flour and other products. (Formerly International Flour Fortification)	Bunge Limited Cargill, Inc.	\$300,000.00	\$113,500.00	
					\$300,000.00		
			Prior Years Funding Partner(s):	Micronutrient Initiative		\$37,861.08	
			AkzoNobel N.V.				
			Australian Department of Foreign Affairs and Trade				
			Bresky Foundation				
			Bühler Group				
			Cargill, Inc.				
			Fortitech General Mills, Inc.				
			Global Alliance for Improved Nutrition				
			Granotec Chile S.A.				
			Hexagon Nutrition Pvt. Ltd.				
			Höganäs AB				
			Industrial Metal Powders				
			International Association of Operative Millers				
			Micronutrient Initiative				
			Navkar bio-chem				
			PD Bros				
			UNICEF				
						Revis	ed: 11142016

CDC Foundation Active Programs

							_
	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Dui	ring CDC Fiscal Year 2016)		(All Years)
			Various Individual Contributors				
93	11/1/2008	3/31/2016	Foodborne Illness Prevention				
			To increase collaboration across the country and across relevant areas of expertise to reduce foodborne illness in the United States.				\$27,000.00
			Prior Years Funding Partner(s):				
			McDonald's Corporation				
			YUM! Brands, Inc.				
94	11/1/2014	3/31/2016	Fortification Assessment Coverage Tool Surveys				
			To assess the coverage and performance of large-scale food fortification programs in Nigeria, South Africa and Uganda through a series of Fortification Assessment Coverage Tool (FACT) surveys.				\$363,196.00
			Prior Years Funding Partner(s): Global Alliance for Improved Nutrition				
95	3/1/2016	3/31/2017	GAVI Alliance Partner Engagement Framework				
			To conduct vaccine research and surveillance with several countries to determine the burden of vaccine preventable diseases, including meningitis, rotavirus, pneumonia, intussusception and rubella. The partnership will enhance the quality of disease and coverage data and assess vaccine impact.	Global Alliance for Vaccines and Immunization	\$2,254,431.00		\$2,254,431.00
96	12/18/2013	12/31/2017	Genomic Epidemiology of Neisseria Gonorrhoeae				
			To study demographic data and Neisseria gonorrhoeae isolates collected as part of the Gonococcal Isolate Surveillance Project and to look at within-host diversity in an ongoing study of extra-genital gonococcal infection.				\$25,921.00
			Prior Years Funding Partner(s):				
			Partners HealthCare System, Inc.				
97	7/1/2002	7/31/2016	Get Smart: Know When Antibiotics Work Campaign				
			To support the CDC's national campaign to promote discriminating use of antimicrobial agents. The campaign seeks to change behavior that leads to overuse of antimicrobial agents in adult and pediatric patients.			Revise	\$1,592,201.50 d: 11142016

CDC Foundation Active Programs

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description				Funding
			Prior Years Funding Partner(s):				
				(D	Ouring CDC Fiscal Year 2016)		(All Years)
					,		,
			Prior Years Funding Partner(s):				
			Abbott Laboratories				
			Advanstar Communications, Inc.				
			Aventis Pharmaceuticals, Inc.				
			Bayer				
			Daiichi Pharmaceutical Company, Ltd.				
			GlaxoSmithKline Biologicals				
			Hoffmann-La Roche Inc.				
			Ortho-McNeil Pharmaceutical, Inc.				
			Pfizer Inc.				
98	3/1/2015	12/31/2016	Ghana Pilot Study-Early Pesticides Exposure				
			To quantify exposure to pyrethroids and organophosphate pesticides in pregnant women and				\$15,577.79
			children in rural Ghana.				
			Prior Years Funding Partner(s):				
			Massachusetts General Hospital				
99	9/1/2012	8/30/2016	Global Burden of Foodborne Norovirus				
33	J, 1, 2012	0,30,2010	To estimate incidence rates of gastroenteritis due to norovirus by age and country/WHO region;				\$14,990.00
			to describe and quantify the available data on health effects resulting from these infections; to				, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
			estimate the proportion of norovirus that is foodborne; and to provide a critical appraisal of data				
			gaps.				
			Prior Years Funding Partner(s):				
			World Health Organization				
100	12/1/2012	ongoing	Global Compassion Fund for Locally Employed Staff				
			This named fund intends to provide modest financial relief to the spouses and dependent children of current CDC locally employed staff (LE Staff) who die or are permanently disabled.	Various Individual Contributors		\$175.00	\$4,213.00
			of current CDC locally employed staff (LE Staff) who die of are permanently disabled.				
			Prior Years Funding Partner(s):				
			Various Individual Contributors				
				-		Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
				_			_
101	12/1/2011	12/31/2016	Global Hepatitis Technical Assistance				4000 044 00
			To expand CDC's capacity to support the development of a WHO Global Hepatitis Program and serve as a resource for individual countries for their viral hepatitis prevention and vaccination activities.				\$832,916.00
			Prior Years Funding Partner(s):				
			Merck & Co., Inc.				
102	11/1/2006	12/31/2016	Global Monitoring of the Tobacco Epidemic				
			To create, launch and expand - as a component of the Bloomberg Initiative to Reduce Tobacco Use - a standard global surveillance system to monitor adult tobacco use and key tobacco control measures in countries with the highest burden from the tobacco epidemic. Data will be used to develop, implement and evaluate tobacco control policies and interventions that can reduce tobacco use at the national and global levels. Prior Years Funding Partner(s): Bloomberg Philanthropies Michael Bloomberg				\$83,850,628.00
103	6/1/2016	6/30/2017	Global Rotavirus and IBVPD Reference				
			To help CDC serve as a Global Reference Laboratory for the rotavirus and the invasive bacterial vaccine preventable diseases (IBVPD) laboratory networks, which provide support to the WHO-coordinated global rotavirus and the global IBVPD surveillance networks.	World Health Organization	\$315,650.00		\$315,650.00
104	12/1/2009	12/31/2017	Global Rotavirus Reference Laboratory				
			To help CDC serve as a Global Reference Laboratory for the rotavirus laboratory network, which provides support to the global rotavirus surveillance network coordinated by the World Health Organization. Prior Years Funding Partner(s): World Health Organization				\$1,206,514.00
1						Revised:	11142016

CDC Foundation Active Programs (October 1, 2017, Contember 20, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	Ouring CDC Fiscal Year 2016)		(All Years)
105	12/1/2009	12/31/2015	Global VPIBD Reference Laboratory				
200	22, 2, 2005	==,0=,=0=0	To help CDC serve as a Global Reference Laboratory for the vaccine-preventable invasive bacterial diseases (VPIBD) laboratory network, which provides support to the global VPIBD surveillance network coordinated by the World Health Organization.				\$1,388,198.00
			Prior Years Funding Partner(s):				
			World Health Organization				
106	8/1/2014	6/30/2016	Griffithsin-based Rectal Microbicides Study				
			To evaluate the effectiveness of the Griffithsin gel treatment on the rectal mucosal environment. Prior Years Funding Partner(s): University of Louisville Research Foundation	University of Louisville	\$209,539.00		\$536,334.00
107	3/1/2016	7/29/2016	Group B Streptococcus Vaccine Development				
			To provide technical assistance to WHO's Initiative for Vaccine Research (IVR) to further group B streptococcus (GBS) vaccine development for low and middle income countries that cannot implement intrapartum antibiotic prophylaxis.	World Health Organization	\$48,082.00		\$48,082.00
108	11/1/2014	12/31/2020	Malaria Zero				
			To eliminate malaria in Haiti by 2020 by developing, adopting and implementing an evidence-based strategy and operational plan, securing resources and improving and refining malaria surveillance systems in Hispanola. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation Various Individual Contributors	Bill & Melinda Gates Foundation Various Individual Contributors	\$520,288.00	\$4,549.00	\$30,527,066.00
109	9/1/2015	9/30/2016	Hand Hygiene Education in U.S. Healthcare				
			To improve hand hygiene outreach in U.S. healthcare facilities by providing hand hygiene educational materials and tools for patients, healthcare providers and caregivers in U.S. healthcare facilities such as hospitals, nursing homes and other ambulatory care locations. Prior Years Funding Partner(s): GOJO Industries, Inc.			Revised: :	\$ 200,000.00

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	ring CDC Fiscal Year 2016)		(All Years)
110	11/1/2012	7/31/2016	HBV and HCV Early Identification and Linkage to Care				
			To provide funding to expand the capacity of community-based organizations to increase early identification of persons with HBV and HCV infections and improve linkage to care, treatment, and preventive services for persons with these infections, as recommended by CDC's Division of Viral Hepatitis.				\$952.448.00
			Prior Years Funding Partner(s):				
			Bristol-Myers Squibb Company				
			Genentech, Inc. Gilead Sciences, Inc.				
111	3/1/2016	2/28/2017	Health Consequences of Marijuana				
			To develop a comprehensive, in-depth systematic review of existing evidence regarding health consequences of marijuana use, as well as to identify a short- and long-term research agenda focused on improving the understanding of the potential association of marijuana use with acute and chronic health outcomes.	Mat-Su Health Foundation State of Alaska State of California The Colorado Health Foundation The Robert W. Woodfruff Foundation Truth Initiative	\$100,000.00 \$250,000.00	\$15,000.00 \$10,000.00 \$500,000.00 \$50,000.00	\$925,000.00
	21/102/2						
112	2/1/2016	7/31/2017	Health Effects of Chemical Exposure To characterize the exposure profiles for most of the environmental chemicals measured in the	Boston University	\$46,000.00		\$46,000.00
			National Health and Nutrition Examination Survey (NHANES) from the first fifty women who enroll in a prospective cohort study of endocrine disrupting chemicals and reproductive health conducted in Denmark.	Boston University	\$40,000.00		\$40,000.00
113	1/1/2014	4/30/2016	Health Outcomes and Measures of the Environment				
			To analyze data through the Health Outcomes and Measures of the Environment (HOME) study, a prospective birth cohort of mothers and their children from Cincinnati, Ohio, who have been followed from the second trimester of pregnancy until the child is around 8 years old. Prior Years Funding Partner(s): Brown University	Brown University	\$164,236.15		\$531,160.05
			Simon Fraser University				

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				((During CDC Fiscal Year 2016)		(All Years)
			University of Cincinnati				
114	1/1/2004	ongoing	Healthy Swimming in the United States				
			To conduct research on chemical, microbiologic and sampling/testing aspects pertinent to the spread of illnesses associated with the use of treated recreational water venues such as pools, hot tubs and water parks. Prior Years Funding Partner(s):				\$422,451.00
			American Chemistry Council				
			Arch Chemicals, Inc.				
			Chem-Aquascience, Inc.				
			ESSRX				
			Lupin Pharmaceuticals, Inc.				
			National Swimming Pool Foundation Slack, Inc.				
115	12/1/2013	12/31/2016	Heart Disease and Stroke Prevention Campaign				
			To develop a national cardiovascular prevention campaign in alliance with the Million Hearts® initiative and the Division for Heart Disease and Stroke Prevention to encourage more Americans to engage with their healthcare providers to address the "ABCs" of heart health and identify lifestyle behaviors that increase the risk of cardiovascular disease and stroke.				\$1,000,000.00
			Prior Years Funding Partner(s):				
			Pfizer Inc.				
116	8/1/2014	12/31/2016	Hepatitis C Testing Stakeholder Panels				
			To conduct stakeholder panels with the goal of supporting the implementation of CDC's Hepatitis C testing recommendations for individuals born from 1945-1965.				\$150,000.00
			Prior Years Funding Partner(s):				
			AbbVie Inc.				
117	4/1/2016	6/30/2020	High Fat Diet and Oxybenzone in Breast Cancer Risk				
11/	7/ 1/ 2010	0/30/2020	Then fac blet and Oxybenzone in breast cancer hisk				

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	Ouring CDC Fiscal Year 2016)		(All Years)
			To investigate the potential association between high fat diet and benzophenone as risk factors for breast cancer.	Michigan State University	\$72,085.00		\$72,085.00
118	12/1/2009	ongoing	Hormone Laboratory Collaborations				
			To help CDC provide reference and quality control materials for laboratory collaboration, including	AB SCIEX LLC		\$17,451.00	\$3,234,074.32
			collaborations for the Hormone Measurement Standardization program.	Abbott Laboratories		\$26,153.00	
			Prior Years Funding Partner(s):	ARUP Laboratories		\$7,928.00	
			AB SCIEX LLC	Beckman Coulter, Inc.		\$20,940.00	
			Abbott Laboratories				
			American Association for Clinical Chemistry American University of Beirut	Bio-Rad Laboratories, Inc.		\$23,970.00	
			Ann & Robert H. Lurie Children's Hospital of Chicago	BioReference Laboratories, Inc.		\$24,430.00	
			Annar Diagnostica	BMH Holdings LLC (TMS BioScience Labs)		\$350.00	
			ARUP Laboratories	Cardiff and Vale University Health Board		\$2,792.00	
			Beckman Coulter, Inc. Bio-Rad Laboratories, Inc.	Centre Hospitalier Universitaire of Liege		\$13,960.00	
			BMH Holdings LLC	Covance		\$28,868.00	
			Boston Medical Center	Craft Technologies, Inc.		\$6,980.00	
			Centre Hospitalier Universitaire of Liege	DiaSorin Inc.		\$19,346.00	
			Centre of Reproductive Medicine and Andrology of the University Cerilliant Corporation	Douglass Hanly Moir Pathology		\$6,980.00	
			Chromesystems Instruments & Chemicals GmbH	Fujirebio Diagnostics, Inc		\$13,960.00	
			Chungnam National University	Fujirebio Inc.		\$6,980.00	
			Clinical Pathology Laboratories, Inc. College of American Pathologist Foundation	Grupo Fleury		\$6,980.00	
			College of American Pathologists College of American Pathologists	Immunodiagnostic Sytems Inc.		\$21,055.00	
			Copenhagen University Hospital	Immunotech S.A.S.		\$22,686.00	
			Covance	Laboratory Corporation of America Holdings		\$31,410.00	
			Craft Technologies, Inc. DiaSorin Inc.	Los Angeles Biomedical Research Institute		\$6,980.00	
			DIAsource Immunoassays	Microgenics Corporation		\$20,940.00	
			Douglass Hanly Moir Pathology	National Institutes of Health		\$6,980.00	
			Endoceutics, Inc.	Oklahoma State University		\$872.54	
			Endocrine Sciences Inc. Esoterix, Inc	Partners HealthCare System, Inc.		\$13,960.00	
			Euroimmun Medizinische Labordiagnostika AG	Pathology Associates Medical Laboratories		\$12,216.00	
			Fred Hutchinson Cancer Research Center	QLoudLab SA		\$4,057.00	

CDC Foundation Active Programs

CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
			(D	uring CDC Fiscal Year 2016)		(All Years)
		Fujirebio Diagnostics, Inc Fujirebio Inc. Gangnam Severance Hospital, Yonsei University Health Canada Heartland Assays LLC Immunodiagnostic Sytems Inc. Immunotech S.A.S. inVentiv Health Clincial Lab Inc. Johns Hopkins University Kaiser Permanente Konkuk University of Medicine and Medical Center Laboratorie National de Metrologie et d'Essais Laboratory Alliance of Central New York Laboratory Corporation of America Holdings Los Angeles Biomedical Research Institute Mayo Foundation for Medical Education and Research Microgenics Corporation Micromass UK Ltd NanoEnTek Inc. New England Research Institutes, Inc. Opko Diagnostics, LLC Partners HealthCare System, Inc. Pathology Associates Medical Laboratories Quest Diagnostics RCPA Quality Assurance Programs Pty Limited Reprosource Fertility Diagnostics Roche Diagnostics Corporation Sahlgrenska University Hospital Seoul Medical Science Institute Siemens USA Social & Scientific Systems, Inc. Taylor Technology, Inc. The University of Western Australia Theranos Tosoh Bioscience, Inc. Tosoh Corporation Tricore Reference Laboratories University College Cork University College Cork University of California, San Francisco	Quest Diagnostics Quidel Corporation Roche Diagnostics Corporation Sahlgrenska University Hospital Siemens USA St. Elizabeth Healthcare Tosoh Corporation University College Cork University of Minnesota The University of Western Australia Waters Ireland LTD ZRT Laboratory, LLC		\$14,150.00 \$3,490.00 \$21,976.00 \$6,963.20 \$80,591.00 \$20,940.00 \$6,980.00 \$8,564.00 \$27,922.00 \$13,960.00 \$13,914.00 \$6,980.00	
					Revised:	11142016

CDC Foundation Active Programs

	CDCE Stort	Droinstad	Drogram	Funding Dortner	Committed Award	Cach	Cumulativa
	CDCF Start	Projected	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Prior Years Funding Partner(s):				Funding
					Overing CDC Final Value 2045)		(4112/22.11)
				(L	During CDC Fiscal Year 2016)		(All Years)
			University of Copenhagen University of Helsinki University of Maryland, Baltimore University of Minnesota University of Washington VU University Medical Center Amsterdam Waters Corporation Waters Corporation XCellAssay, LLC Zeus Scientific, Inc. ZRT Laboratory, LLC				
119	8/1/2012	7/30/2016	HPV Genotyping and Immunogenicity Measures				
			To enable CDC to provide technical and analytical expertise in HPV genotyping and immune response measurements to academic and other partners in need of these assays to advance public health objectives related to HPV vaccine impact monitoring and HPV epidemiology. Prior Years Funding Partner(s): Cincinnati Children's Hospital Medical Center Emory University Serum Institute of India Ltd. University of Alberta University of Puerto Rico				\$54,071.54
120	3/1/2015	5/31/2016	Hyperuricemia in American Indian Families				
	5, 2, 2025	3, 32, 2320	To study the effect of environmental pollutants in American Indians in an effort to investigate their effect on hyperuricemia by themselves or in interaction with genetic factors. Prior Years Funding Partner(s): University of North Carolina at Chapel Hill				\$116,780.20
				•		Revised: 1	11142016

CDC Foundation Active Programs

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description				Funding
			Prior Years Funding Partner(s):				
				(n	Ouring CDC Fiscal Year 2016)		(All Years)
					dring CDC riscal real 2010)		(All Teals)
121	3/1/2015	7/30/2018	Impact of Environmental Exposures in Children				
			To investigate the potential impact of exposure to environmental chemicals on				\$364,845.00
			neurodevelopmental outcomes in children with congenital heart defects.				
			Prior Years Funding Partner(s):				
			The Children's Hospital of Philadelphia				
122	2/1/2014	12/31/2017	Impact of Flame Retardant Exposure on Children				
	. ,	, ,	To measure serum levels of polybrominated diphenyl ethers (PBDE), polychlorinated biphenyls				\$295,576.75
			(PCBs) and pesticides in 850 children at birth, at 2 to 3 and 5 to 7 years of age. This study will				
			characterize the longitudinal impact of PBDE exposure, commonly known as flame retardant, occurring throughout childhood on neurodevelopment.				
			occurring throughout chilumood on neurodevelopment.				
			Prior Years Funding Partner(s):				
			Columbia University				
123	7/1/2015	6/30/2019	Impact Study of Rotavirus Vaccine in India				44 572 505 00
			To generate data on the effectiveness and impact of rotavirus vaccination in early introducing regions of India and help establish a platform for assessment of safety with respect to				\$1,673,595.00
			intussusception.				
			Prior Years Funding Partner(s): Bill & Melinda Gates Foundation				
			Sin & Meinida Gates Foundation				
124	11/1/2013	6/30/2016	Cervical Cancer Screening and Treatment				
			To scale up and improve cervical cancer screening and treatment programs globally through a	Bill & Melinda Gates Foundation	\$580,644.00		\$4,276,785.00
			consortium-based approach-Improving Data for Global Cervical Cancer Screening and Treatment Programs.				
			Prior Years Funding Partner(s):				
			Bill & Melinda Gates Foundation				
125	7/1/2009	9/30/2018	Health Care Provider Performance Review				
123	7/1/2009	3/ 30/ 2010	To generate evidence-based recommendations via a systematic literature review on how to				\$3,125,903.00
			improve health care providers' performance in low-and middle-income countries.				7-7-20/500:00
I				1		Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative Funding
			Prior Years Funding Partner(s):				
				(C	Ouring CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s):				
			Bill & Melinda Gates Foundation				
126	7/1/2013	ongoing	Improving Health Outcomes of LGBT Youth				
			To address critical gaps in knowledge about protective factors and interventions that promote positive health outcomes among lesbian, gay, bisexual and transgender (LGBT) youth, and to possibly improve academic and social outcomes in this population. This project will result in the development and dissemination of publications and other resources that enhance the scientific and programmatic response to HIV, STDs and other sexual health issues among LGBT youth.				\$320,280.00
			Prior Years Funding Partner(s):				
			Arcus Foundation				
			/ ileas i sariaation				
127	9/1/2014	12/31/2016	Improving Hepatitis E Outbreak Control				
			To support a collaboration between CDC, the London School of Hygiene & Tropical Medicine and the United Nations Human Rights Council to partner on a joint proposal to the Research in Health for Humanitarian Crises to improve Hepatitis E outbreak control efforts among emergency affected populations.				\$68,777.66
			Prior Years Funding Partner(s): Enhancing Learning and Research for Humanitarian Assistance				
128	3/1/2015	2/28/2017	Improving Population Health in California				
			To increase private-sector understanding of the role of CDC in population-based health and to build partnerships that advance public health in California and nationally.				\$500,000.00
			Prior Years Funding Partner(s): The California Endowment				
129	7/1/2011	1/31/2016	Improving the Measles Vaccine				
			To provide laboratory support for the development of a more thermostable measles vaccine.				\$48,200.00
			Prior Years Funding Partner(s):				
			Serum Institute of India Ltd.				
			Universal Stabilization Technologies, Inc.	I			11112016
						Revised:	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
				1			ı
130	10/1/2013	5/31/2016	Incinerators Biomonitoring Study				
			To assess the relationship between modeled area level ambient dioxin exposure and individual level breast milk dioxin exposure in residents living near two municipal solid waste incinerators, Marchwood in Hampshire and Stockton-on-Tees in Cleveland, in England. A total of 100 human milk specimens will be analyzed for PCDDs/PCDFs/cPCBs. The study results will additionally help interpret the results of the national epidemiological study on municipal solid waste incinerators and birth outcomes being conducted by the Small Area Health Statistics Unit at Imperial College London. Prior Years Funding Partner(s): Imperial College London				\$55,900.00
131	7/1/2016	8/30/2016	Increasing the Supply of Organs for Georgians				
			To increase the number of organs that are used for transplant in Georgia and the U.S. by using advanced analytics methods for quantifying the risk and comparing survival of receiving a transplant versus remaining on the wait list, and embed these methods into easy-to-use multilingual decision support tools to assist doctors and patients in their decision-making. Overall, this research will lead to a comprehensive plan for increasing organ transplants and saving lives in Georgia and across the country.	Georgia Institute of Technology	\$42,700.00		\$42,700.00
132	7/1/2014	12/31/2017	Infant Feeding, Early Development and Isoflavones				
			To measure approximately 50 infant and toddler urine specimens for phytoestrogens as part of an observational, longitudinal, prospective cohort study with the Children's Hospital of Philadelphia. The study will investigate hormonal endpoints during infancy and toddlerhood in relation to feeding by breast milk, cow-milk based formula or soy-protein based formula. Prior Years Funding Partner(s): National Institute of Environmental Health Sciences				\$7,035.98
133	10/1/2014	9/30/2016	Infant Feeding, Early Development and Phenolics				
			To investigate the early life estrogen-dependent endocrine disruption in relation to exposure to triclosan, methyl paraben, propyl paraben and other personal care product compounds.				\$45,125.21
			Prior Years Funding Partner(s):				
			National Institute of Environmental Health Sciences	I		Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Social Scientific Systems, Inc.				
134	9/1/2015	8/31/2016	Integrated Rotavirus Vaccine Development Plan				
			To implement a robust product development program for an integrated, inactivated rotavirus vaccine in low-income countries. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation				\$499,628.00
135	12/1/2013	12/31/2016	Intervention Study in Guatemala				
			To design and execute an intervention study to address severe morbidity due to diarrhea and intestinal parasites in children under 5 in Guatemala. Prior Years Funding Partner(s): Global Health Partnership Initiative				\$78,745.00
136	3/1/2015	5/31/2016	Investigating Chlorine Dioxide as Disinfectant				
			To evaluate the use of chlorine dioxide as a disinfectant in recreational water venues. Prior Years Funding Partner(s): National Swimming Pool Foundation				\$37,565.00
137	1/1/2014	8/31/2016	Investigating Chronic Kidney Disease in Nicaragua				
			To facilitate collaboration and investigate the potential of non-occupational causes of chronic kidney disease in Nicaragua in connection with the Chronic Kidney Disease Research initiative in Central America. Prior Years Funding Partner(s): Comité Nacional de Productores de Azúcar				\$674,328.00
138	11/1/2009	ongoing	KSHV in Sub-Saharan Africa				
			To test blood and saliva samples from Uganda, Zimbabwe and South Africa for Kaposi sarcoma-associated herpesvirus (KSHV) antibodies and DNA; to measure KSHV seroprevalence and			Revised:	\$127,355.00 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative Funding
			Prior Years Funding Partner(s):	(1	During CDC Fiscal Year 2016)		(All Years)
			seroincidence; to analyze determinants of KSHV infection; and to examine the response of KSHV infection to antiretroviral therapy. Prior Years Funding Partner(s): University of California, San Francisco				
139	10/1/2013	11/30/2016	Laboratory Surveillance for Factor XIII Deficiency				
	, ,	, ,	To provide support for Factor XIII testing to accurately diagnose patients in the United States in order to enhance the surveillance of rare bleeding disorders. Prior Years Funding Partner(s): Novo Nordisk Inc.				\$152,975.00
140	4/1/2013	12/31/2016	Labs for Life Fellowship				
	7.7 -3-3	23,03, 2020	To support CDC's Center for Global Health on the five-year public-private partnership between BD and PEPFAR focused on improving overall laboratory systems and services in Uganda, Ethiopia, Kenya, Mozambique and India, countries severely affected by HIV/AIDS and tuberculosis. Prior Years Funding Partner(s): BD	BD		\$25,932.41	\$266,391.41
141	9/1/2013	3/31/2017	Healthy People 2020 Law and Health Policy Project				
			To develop progress reports linked to Healthy People 2020 (a science-based, 10-year national objective for improving the health of Americans) to demonstrate the value of legal and policy interventions in improving Americans' health. Prior Years Funding Partner(s): Robert Wood Johnson Foundation				\$1,629,622.00
142	5/1/2014	7/30/2016	Leveraging Data for Hepatitis C Surveillance				
			To strengthen surveillance for hepatitis C (HCV) infection by using commercial lab data to obtain, analyze and disseminate data on HCV testing. This project will complete an analysis of non-invasive markers for liver fibrosis in the dataset to estimate the stage of liver disease for persons newly positive for HCV.				\$198,824.00
						Revised: 1	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	uring CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s):	1			1
			AbbVie Inc.				
143	9/1/2013	6/30/2016	Leveraging Rotavirus Networks				
			To determine the performance characteristics of tacrolimus-based (TAC) genotyping in comparison to conventional genotyping assays to better assess the role of different enteric pathogens in diarrhea requiring hospitalization among children less than five years of age. The technology will advance the analysis of rotavirus vaccine effectiveness studies by revealing how often cases of rotavirus vaccine failure are actually infections due to other enteric pathogens.	Bill & Melinda Gates Foundation	\$2,819,232.00		\$4,319,223.00
			Prior Years Funding Partner(s):	1			1

			AbbVie Inc.			
143	9/1/2013	6/30/2016	Leveraging Rotavirus Networks			
			To determine the performance characteristics of tacrolimus-based (TAC) genotyping in comparison to conventional genotyping assays to better assess the role of different enteric pathogens in diarrhea requiring hospitalization among children less than five years of age. The technology will advance the analysis of rotavirus vaccine effectiveness studies by revealing how often cases of rotavirus vaccine failure are actually infections due to other enteric pathogens. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation	\$2,819,232.00	\$4,319,223.00
144	8/1/2016	9/30/2016	Lowell Healthy Homes Program			
			CDC's Tobacco and Volatiles Branch will measure cotinine levels in 180 urine samples from elders living in public housing in Lowell, MA in order to assess the effectiveness of a smoking ban.	University of Massachusetts Lowell	\$16,560.61	\$16,560.61
145	4/1/2011	6/30/2016	Lymphatic Filariasis Morbidity Control in Mali			
			To reduce disability and improve the quality of life for those experiencing chronic complications of lymphatic filariasis in sub-Saharan Africa by providing access to a lymphedema management program in Mali. Prior Years Funding Partner(s): Izumi Foundation			\$152,000.00
146	8/1/2015	8/31/2018	Making Dialysis Safer for Patients			A
			To reduce potentially deadly bloodstream infections in hemodialysis outpatients by targeting patients, healthcare providers and caregivers using evidence-based communications strategies with prevention messages. Prior Years Funding Partner(s): Amgen Inc.			\$456,000.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
147	1/1/2013	9/30/2016	Malaria Host-Pathogen Interaction Center (MaHPIC)				
			To study and catalog in molecular detail how malaria parasites interact with their human and other animal hosts and cause disease using the "systems biology" approach. The project will integrate data generated by malaria research, functional genomics, proteomics, lipidomics and metabolomics cores, with the aid of informatics and computational modeling cores. CDC will be providing project support by generating proteomic data in the context of the project's Proteomics Core and the Malaria Core. Prior Years Funding Partner(s): Emory University	Emory University	\$56,105.00		\$355,865.00
148	12/1/2007	ongoing	Malaria in Pregnancy				
			To evaluate the impact of malaria on pregnancy outcomes in Latin American countries. Prior Years Funding Partner(s): Emory University Liverpool School of Tropical Medicine				\$2,579,770.34
149	7/1/2002	3/31/2017	Malaria Research and Reference Reagent Repository				
			To support a mosquito stock repository that supplies living and preserved laboratory cultured malaria-vector mosquitoes to researchers studying malaria. Prior Years Funding Partner(s): Acme Cargo Express Singapore Addia Ababa University American Embassy American Type Culture Collection Claflin University Duke University Institute of Tropical Medicine International Center for Vaccine Foundation Kanazawa University				\$5,152,526.23 d: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					Ouring CDC Fiscal Year 2016)		(All Years)
			Kwame Nkrumah University of Science & Technology London School of Hygiene and Tropical Medicine National Institute of Malaria Research National Research Center ETDE for Training on Malaria Snell Scientifics, LLC Springborn Smithers Laboratories The Rockefeller University University of Bamako University of Bergen University of California University of California, Davis University of Florida University of Notre Dame Université de Bandundu				
150	12/1/2010	ongoing	Malaria Research Programs				
		5 5	Use for contributions received for malaria research; but not program specific. Prior Years Funding Partner(s): Various Individual and Organizational Contributors				\$7,075.00
151	3/1/2016	3/31/2016	Maternal and Perinatal Death Surveillance				
			To reduce maternal and perinatal death globally through strengthening implementation of Maternal and Perinatal Death Surveillance and Response (MPDSR) systems and advise WHO and partners on guidance, standards of practice and tools to help achieve the post-MDG maternal and newborn goals and targets.	World Health Organization	\$47,560.00		\$47,560.00
152	10/1/2012	1/30/2016	Maternal Death Surveillance and Response				
			To enable CDC experts to contribute to an international collaboration to reduce maternal deaths through training and implementation support and to contract a local maternal and child health expert to provide continuous, on-the-ground support to ministries of health in East Africa.				\$81,725.00
						Rev	ised: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): World Health Organization				
153	11/1/2015	11/30/2016	Maternal Mortality Review Data System	A4	62 202 450 00		42 202 450 00
			To increase the United States' capacity to use data for preventing maternal mortality.	Merck Sharp & Dohme Corp.	\$2,392,458.00		\$2,392,458.00
154	5/1/2013	5/30/2017	Maternal Organics Monitoring Study				
			To collect and analyze blood, cord and urine samples from 200 Alaska Native mother-infant pairs over the period of one year. The levels of persistent organic pollutants, heavy metals, cytokines, selenium and a fatty acid profile in pregnant women and newborn infants will be measured, as will levels of radioactive isotopes, phthalate, mercury, arsenic, polycyclic aromatic hydrocarbons and phytoestrogensin. Prior Years Funding Partner(s): Alaska Native Tribal Health Consortium				\$156,217.75
155	3/1/2008	10/31/2017	Measuring PAHs in a Cohort of NYC Women and Children				4500.040.04
			To evaluate whether exposure to PAHs during pregnancy adversely affects fetal development, asthma development and child health. Prior Years Funding Partner(s): Columbia University				\$596,242.01
156	10/1/2013	10/31/2019	MenAfriNet Meningitis Surveillance in Africa				4
			To establish a regional surveillance network - MenAfriNet - to collect and analyze high quality case-based meningitis surveillance data from representative sites across the African meningitis belt. The meningitis surveillance network will evaluate the impact of MenAfriVac to guide research on new vaccines and strategies to optimize impact of existing vaccines. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation			Pariand, 4	\$9,999,999.00
i						Revised: 1	1142010

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description Prior Years Funding Partner(s):				Funding
				(D	uring CDC Fiscal Year 2016)		(All Years)
157	7/1/2016	11/30/2018	Meningitis Carriage Study in Burkina Faso				1
	,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	To conduct an evaluation of N. Meningitidis and N. Lactamica in Burkina Faso as part of a larger initiative to introduce a novel serogroup A conjugate meningococcal vaccine in Africa and eliminate epidemic meningitis.	Bill & Melinda Gates Foundation	\$654,215.00		\$654,215.00
158	12/1/2015	Ongoing	Microbicide Intrauterine System for HIV Prevention				
			To perform preclinical research targeted towards HIV prevention in women.	CONRAD		\$11,054.00	\$11,054.00
159	10/1/2014	5/31/2016	Monitoring and Evaluating "Head Safe, Helmet On"				
			To provide technical assistance with the monitoring and evaluation of the U.S. Agency for International Development (USAID) program "Head Safe, Helmet On," which promotes safety and the use of helmets for drivers, passengers and children in targeted provinces in Cambodia. Prior Years Funding Partner(s): Asia Injury Prevention Foundation				\$18,800.00
160	5/1/2010	5/31/2016	Monitoring Malaria Treatment in the U.S.				
			To collect, manage and analyze data on the safety and efficacy of artemether/lumefantrien used to treat cases of malaria in the U.S. Prior Years Funding Partner(s): Novartis Pharmaceuticals Corporation				\$555,382.00
161	10/1/2012	12/31/2015	Monitoring the Tobacco Epidemic in Africa and Southeast Asia				
			To conduct repeat GATS surveys in priority countries and implement tobacco questions for surveys in both regions. Prior Years Funding Partner(s): Bloomberg Philanthropies				\$2,000,000.00
162	9/1/2015	12/31/2016	Mortality Surveillance in Acute Emergencies				
			To establish new collaborations and strengthen partnerships between CDC, Save the Children Foundation in the United States, Save the Children Foundation International, UN agencies and other major humanitarian partners for the purpose of implementing and evaluating two community-based methods of mortality data collection.	Enhancing Learning and Research for Humanitarian Assistance		\$13,336.26 Revised:	\$13,336.26

CDC Foundation Active Programs

						Funding
			(Du	ring CDC Fiscal Year 2016)		(All Years)
9/1/2016	8/30/2017	Mosquito Cryopreservation and Female Elimination				
		To support cryopreservation and suppression of female development in mosquitoes to assist research for malaria control.	Good Ventures Foundation (The Clear Fund)	\$1,214,436.78		\$1,214,436.78
8/1/2013	11/30/2017	Multistate Fungal Meningitis Outbreak Management				
		To respond to an unprecedented outbreak of central nervous system, joint and osseous mold infections that have been observed, beginning in August of 2012, among hundreds of patients who received contaminated methylprednisolone injections. This project will collect long-term follow-up data on diagnosis and appropriate treatment of fungal meningitis and other fungal infections associated with this outbreak in order to fully understand and track the burden of these infections. Prior Years Funding Partner(s): Gilead Sciences, Inc. Springer Science + Business Media LLC				\$104,800.00
12/18/2013	ongoing					4:00.000.00
		To facilitate collaborative development of a newborn bloodspot screening test to detect the genetic lesions that cause spinal muscular atrophy. The test will be designed to use with public health newborn screening laboratories. Prior Years Funding Partner(s): Biogen Idec				\$100,000.00
2/15/2006	12/21/2016	Nawborn Screening Translation Passarch Initiative				
3) 13) 2000		To improve four major areas of newborn screening: 1) developing new screening methods for specific diseases, 2) integrating state public health laboratories in the translation process through collaborative field studies, 3) expanding the global reach of newborn screening, and 4) adapting innovative technologies for screening and quality assurance. Prior Years Funding Partner(s): Genzyme Corporation PerkinElmer, Inc. Various Individual Contributors	Genzyme Corporation	\$254,000.00		\$2,677,000.00
		8/1/2013 11/30/2017 12/18/2013 ongoing	To support cryopreservation and suppression of female development in mosquitoes to assist research for malaria control. 8/1/2013 11/30/2017 Multistate Fungal Meningitis Outbreak Management To respond to an unprecedented outbreak of central nervous system, joint and osseous mold infections that have been observed, beginning in August of 2012, among hundreds of patients who received contaminated methylprednisolone injections. This project will collect long-term follow-up data on diagnosis and appropriate treatment of fungal meningitis and other fungal infections associated with this outbreak in order to fully understand and track the burden of these infections. Prior Years Funding Partner(s): Gliead Sciences, Inc. Springer Science + Business Media LLC 12/18/2013 ongoing Newborn Screening Test for Spinal Muscular Atrophy To facilitate collaborative development of a newborn bloodspot screening test to detect the genetic lesions that cause spinal muscular atrophy. The test will be designed to use with public health newborn screening laboratories. Prior Years Funding Partner(s): Biogen Idec 3/15/2006 12/31/2016 Newborn Screening Translation Research Initiative To improve four major areas of newborn screening: 1) developing new screening methods for specific diseases, 2) integrating state public health laboratories in the translation process through collaborative field studies, 3) expanding the global reach of newborn screening, and 4) adapting innovative technologies for screening and quality assurance. Prior Years Funding Partner(s): Genzyme Corporation PerkinElmer, Inc.	To support cryopreservation and suppression of female development in mosquitoes to assist research for malaria control. Multistate Fungal Meningitis Outbreak Management To respond to an unprecedented outbreak of central nervous system, joint and osseous mold infections that have been observed, beginning in August of 2012, among hundreds of patients who received contaminated methylpredistopione injections. This project will collect long-term follow up data on diagnosis and appropriate treatment of fungal meningitis and other fungal infections associated with this outbreak in order to fully understand and track the burden of these infections. Prior Years Funding Partner(s): Gilead Sciences, Inc. Springer Science + Business Media LLC 12/18/2013 ongoing Newborn Screening Test for Spinal Muscular Atrophy To facilitate collaborative development of a newborn bloodspot screening test to detect the genetic lesions that cause spinal muscular atrophy. The test will be designed to use with public health newborn screening laboratories. Prior Years Funding Partner(s): Biogent Idec To improve four major areas of newborn screening: 1) developing new screening methods for specific diseases, 2) integrating state public health laboraties in the translation process through collaborative field studies, 3) expanding the global reach of newborn screening, and 4) adapting innovative technologies for screening and quality assurance. Prior Years Funding Partner(s): Genzyme Corporation Perkintliner, Inc.	To support cryopreservation and suppression of female development in mosquitores to assist research for malaria control. 8/1/2013 11/30/2017 Multistate fungal Meningitis Outbreak Management To respond to an unprecedented outbreak of central nerview system, joint and ossessus moid infections that have been observed, beginning in August of 2012, among hundreds of patients who received contaminated methylprothisoblance injections. This proper joint and ossessus moid infection can diagnosis and appropriate treatment of fungal meningids and other fungal infections associated with this outbreak in order to fully understand and track the burden of these infections. Prior Years Funding Partner(s): Gliada Stences, Inc. Springer Science - Business Media LLC 12/18/2013 ongoing Newborn Screening Test for Spinal Muscular Atrophy To facilitate collaborative development of a newborn bloodspot screening test to detect the genetic leains that cause spinal muscular atrophy. The test will be designed to use with public health newborn screening bloodsories. Prior Years Funding Partner(s): Spinger Science, 2) integrating subcritories. 7 Improve four major areas of newborn screening: 1) developing new screening methods for specific disousce, 2) integrating subcritories in the translation process through collaborative field studies, 3) expansing the global reach of newborn screening, and quality assurance. Prior Years Funding Partner(s): Genzyme Corporation Genzyme Corporation Genzyme Corporation Genzyme Corporation S254,000.00	Fo support representation and suppression of formule development in monophoes to social cascard for maintain control. 8/1/2013 11/30/2017 Multistate Fungal Meningitis Outbreak Management To rescond to an unprecedented outbreak of creatful increase system, joint and osseable mentions follow-up that an officialism full have beneficially in August of 2012, among hundress of patients who received contaminated methylipredindone in sections. This project will collect fone term follow-up that an officialism. Prior Years Funding Partner(5): Glood Sciences, inc. Soringer Science = Business Media LLC 12/18/2013 ongoing Newborn Screening Test for Spinal Muscular Atrophy Test of Clidates collaborative development of a newborn bloodpot screening test to detect the genetic lesions. In the process of the propriate of a newborn bloodpot screening test to detect the genetic lesions. In the process of the propriate of a newborn bloodpot screening test to detect the genetic lesions. In this case spinal muscular atrophy. The test will be designed to use with public leads and the about no screening Beast for Spinal Muscular Atrophy Prior Years Funding Partner(5): Biogen lists. In uncrose four major areas of newborn screening Tassistation Research Initiality To uncrose four major areas of newborn screening, and 4) adeptine in the translation process through collaborative field studies, 3) expanding the public leads that blood screening in the translation process through collaborative field studies, 3 expanding the poblical research in the translation process through collaborative field studies, 3 expanding the poblical research in the translation process through collaborative field studies, 3 expanding the poblical research in the translation process through collaborative field studies, 3 expanding the poblical research in the translation process through collaborative field studies, 3 expanding the public leads and the studies of the section of the se

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(C	During CDC Fiscal Year 2016)		(All Years)
				·			
167	2/1/2014	2/28/2016	Norovirus and Gastroenteritis Surveillance				
			To expand surveillance of norovirus infection and acute gastroenteritis in a managed-care population to better understand incidence, seasonal patterns, clinical characteristics and the epidemiological profile of the diseases and inform prevention efforts.				\$1,455,210.00
			Prior Years Funding Partner(s): Takeda Pharmaceutical Company Limited				
168	8/16/2007	6/30/2016	Norovirus In-Vitro Time-Kill Evaluation				
			To evaluate commercial sanitizing products for their virucidal effectiveness against murine norovirus.	Applied BioCode, Inc. Diasorin	\$222,430.00	\$55,000.00	\$2,214,320.36
			Prior Years Funding Partner(s):	Luminex Corporation	\$19,865.00	\$33,450.00	
			American Society for Microbiology				
			Arch Chemicals, Inc.				
			Byotrol Inc.				
			Cepheid				
			Clemson University				
			Ecolab				
			GOJO Industries, Inc.				
			Holland America Line				
			IISES, LLC				
			ImpactRx, Inc.				
			Indusco Distribution of America, Inc.				
			International Atomic Energy Agency				
			Luminex Corporation				
			Luminex Molecular Diagnostics, Inc.				
			Microbide Limited				
			Mölnlycke Health Care, LLC				
			Nanosphere, Inc.				
						Revise	d: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Oxoid Ltd. Pathcon Laboratories Procter & Gamble Company R-Biopharm Inc. RADCO Chemical Solutions, Inc. Takeda The University of Queensland, Australia Therapeutic Goods Administration University of North Carolina at Chapel Hill				
169	6/1/2016	12/31/2017	Nutritional Biomarkers Control Materials Testing				
			To perform characterization measurements on multiple aliquots of biological matrices to ensure the accuracy of nutritional biomarkers in controlled blood samples.	Craft Technologies, Inc.	\$42,125.99		\$42,125.99
170	11/1/2013	5/31/2017	NYC Hanes Lab Study				
			Fund for Public Health in New York (FPHNY)/Department of Health and Mental Hygiene of the City of New York as the recipients of the Laboratory Component of the 2013 NYC Hanes (NYC Hanes "Lab Grant") are subcontracting with DVH laboratory team to conduct sophisticated Hepatitis B, C, and E testing on blood specimens. Prior Years Funding Partner(s): Fund for Public Health in New York				\$61,062.40
171	1/1/2014	12/31/2017	Optimizing Helmets to Reduce Work-Related Injuries				6430 000 00
			To optimize helmet design to reduce the severity of head injuries at construction worksites. The study will build on CDC's research of digital human modeling of personal protective equipment and will respond to construction industry-wide needs for effective assessment methods to control exposures resulting in fatal and nonfatal work-related traumatic brain injury. Prior Years Funding Partner(s): ACE Construction Group Liberty Mutual Insurance Turner Construction Company				\$120,000.00
1						Revised: 1	1142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
			Zurich American Insurance Company				
172	11/1/2015	11/30/2018	Opt-Out Chlamydia Screening Effectiveness				
			To explore the effectiveness of opt-out chlamydia screening via electronic health record prompt and to increase the percentage of women under the age of 25 who are screened for chlamydia at clinical encounters.	Hologic Inc.	\$709,002.00		\$709,002.00
173	7/1/2016	9/30/2018	Organophosphate Pesticides in Rural Communities				
			To perform characterization measurements on multiple aliquots of biological matrices to ensure the accuracy of nutritional biomarkers in controlled blood samples.	Catholic University of Maule	\$63,300.00		\$63,300.00
174	6/1/2015	5/31/2016	PAHs Exposure Assessment in Disadvantaged Areas				
			To demonstrate that a passive wristband sampler can be used to quantify personalized exposure to environmental chemicals such as polycyclic aromatic hydrocarbons (PAHs) with higher compliance and equal accuracy compared to an active air sampler, and to show the utility of a mobile phone-enabled application to concurrently capture lung function measurements. Prior Years Funding Partner(s): Columbia University				\$4,471.00
175	4/1/2013	ongoing	Pappaioanou Veterinary Public Health and Applied Epidemiology Fellowship				
			Endowed fund to provide competitively selected veterinarians and 3rd and 4th year veterinary medical students with opportunities in an applied hands-on training experience in epidemiology, public health, or global health. Each fellow will spend up to one full year at CDC in a U.S. focused or global public health program/project. Prior Years Funding Partner(s): Various Individual and Organizational Contributors	Various Individual and Organizational Contributors		\$12,780.00	\$91,054.44
176	9/1/2015	ongoing	Partnership Fund for HPV Genotyping				
			To provide technical and analytical expertise in HPV genotyping and immune response measurements to academic and other partners in need of these assays to advance public health objectives related to HPV vaccine impact monitoring and HPV epidemiology. Prior Years Funding Partner(s):				\$1,349.32
			ViroStat, Inc.				
				•		Revised: :	11142016

CDC Foundation Active Programs

CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
			(D	uring CDC Fiscal Year 2016)		(All Years)
				,		
12/1/2014	12/31/2016			4000 070 00		1200.070.00
		To develop a data collection and analysis tool to assess outcomes of Antimicrobial Stewardship Programs.	Cubist Pharmaceuticals, Inc. (now Merck)	\$988,972.00		\$988,972.00
7/1/2014	7/31/2016	Paul M. Fernhoff Memorial Lecture Series				
		To host an educational and inspirational lecture that continues the legacy of Dr. Paul Fernhoff who shepherded the development of Georgia's newborn screening program, which now monitors every baby born in Georgia for more than 50 genetic disorders. The lecture series will enhance the visibility and expand the potential benefits of newborn screening. Prior Years Funding Partner(s): The Legacy of Angels Foundation				\$24,000.00
8/1/2004	7/31/2016	PCBs. Phthalates and Male Reproductive Health				
-, -, -	1,11,11	To determine if and how exposure to PCBs and phthalates affects male fertility.	Harvard University		\$94,599.58	\$730,870.08
						'
		Prior Years Funding Partner(s):				
		Harvard University				
8/1/2013	9/30/2016	Pneumonia Ftiology Research for Child Health				
0/2/2020	3,33,2323		University of California, Berkeley	\$100,401.92		\$330,011.57
		women and infants.	.,	v,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		Prior Years Funding Partner(s):				
		University of California, Berkeley				'
- 11 1000	- / /					
6/1/2015	2/28/2018					£353.115.00
		with detailed cardiometabolic risk measures.				\$353,115.00
		Prior Vegre Funding Portneyfelt				
			I			
	Date 12/1/2014	12/1/2014 12/31/2016 7/1/2014 7/31/2016 8/1/2004 7/31/2016	12/1/2014 12/31/2016 Patient Tools for Antibiotic Stewardship Programs	Date End Date Program Description Prior Years Funding Partner(s):	Date End Date Program Description Pror Years Funding Partner(s): (During CDC Fiscal Year 2016) 12/1/2014 12/31/2016 Patient Tools for Authoric Stewardship Programs To devise a data collection and analysis toot to assess outcomes of Antimicrobial Stewardship Programs. The devise a data collection and analysis toot to assess outcomes of Antimicrobial Stewardship Programs. The June M. Farnhoff Memorial Lecture Series The bod an externational and ineignational entries that continues the Lagoy of 10, final cambell wints the series of the Continues of the Series of the	Date End Date Program Description Prior Year Funding Partner(s): 12/1/2014 12/21/2015 Patent Tools for Antibiotic Stawarding Program: To develop a data collection and an eye's bot to eases outcomes of Antibiotic Stawarding Program: To develop a data collection and an eye's bot to eases outcomes of Antibiotic Stawarding Program: To develop a data collection and an eye's bot to eases outcomes of Antibiotic Stawarding Program: To develop a data collection and an eye's bot to eases outcomes of Antibiotic Stawarding Program: To the an excellation and dayspiration statute Series To host an excellation and dayspiration statute Series To host an excellation and dayspiration statutes Series To host an excellation and dayspiration statutes of the color ancess of the color ancess of an excellation of the color ancess of the color ancess of an excellation of the color ancess of a color and the color ancess of a color and the color and the color ancess of a color and the color and the color ancess of a color and the color and th

CDC Foundation Active Programs

(October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	uring CDC Fiscal Year 2016)		(All Years)
182	3/1/2015	9/1/2016	Perfluorocarbon Exposures in Urban Firefighters				
			To establish a reliable picture of the range, median tendency and predictors of perfluorocarbon (PFC) exposures in urban firefighters, and to establish how well the findings independently predict intermediate markers of cardiovascular and respiratory health. Prior Years Funding Partner(s): West Virginia University				\$5,470.40
183	6/1/2015	6/30/2017	Permethrin Exposure: Biomarkers and Dosimetry				
	0, 1, 2010	3/30/2027	To investigate determinants that significantly influence exposure to permethrin among military personnel, a critical step to provide valid predictive models and accurate policy guidance to mitigate any potential health risks associated from the use of permethrin-treated clothing. Prior Years Funding Partner(s): Henry M. Jackson Foundation for the Advancement of Military Medicine (US Army Research Institute of Environmental Health)	Henry M. Jackson Foundation for the Advancement of Military Medicine	27,526.40		\$229,926.40
184	11/1/2015	7/31/2016	Persistent Organic Pollutants and Cognitive Aging				
			To measure persistent organic pollutants (POPs) and provide data on the relation of POPs to accelerated cognitive aging.	The George Washington University Rush University Medical Center	\$4,340.44 \$10,224.00		\$14,564.44
185	8/1/2016	7/30/2017	Pesticide Exposure in Migrant Farmworkers				
			To evaluate pesticide exposure in farmworkers as a function of heat stress and hydration levels in summer vs. winter.	The University of Arizona	\$4,000.00		\$4,000.00
186	10/1/2012	10/31/2016	PET-C: HCV in Opiate Agonist Treatment Settings				
			To evaluate the acceptance and utility of telemedicine as a method to deliver hepatitis C virus (HCV) management to patients, with the addition of education, prevention, and awareness efforts as a multi-pronged treatment approach among patients on methadone maintenance. Prior Years Funding Partner(s): Abbott Laboratories Vertex Pharmaceuticals, Incorporated				\$325,000.00
1						Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award Ouring CDC Fiscal Year 2016)	Cash	Cumulative Funding (All Years)
				(9	dring CDC riscal real 2010)		(All Teals)
187	3/1/2008	9/30/2017	Phones for Health				
			To leverage mobile technology to fight HIV/AIDS, TB, malaria and other diseases in 10 developing countries supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Prior Years Funding Partner(s): Bill & Melinda Gates Foundation Centers for Disease Control and Prevention Motorola Foundation Voxiva				\$17,875,190.73
188	10/1/2014	12/31/2016	Phthalate Biomarkers and Pregnancy				
			To explore the relationship between maternal environmental chemical exposure and hormone levels at different stages of pregnancy. Prior Years Funding Partner(s): Brown University Women & Infants Hospital of Rhode Island	Brown University	\$30,000.00		\$80,408.50
189	3/1/2015	12/1/2017	Phthalate Exposure and Preeclampsia				
			To use the Combined Antioxidant and Preeclampsia Prediction Study (CAPPS) database and biospecimens to investigate the potential association between phthalate exposure and preeclampsia. Prior Years Funding Partner(s): Women & Infants Hospital of Rhode Island				\$6,468.40
190	6/1/2015	2/29/2016	Phthalate Exposure in Adults				
			To evaluate the potential association between exposure to phthalates and the development of diabetes and obesity in adults. Prior Years Funding Partner(s): University of Illinois at Chicago			Revised: 1	\$12,290.26 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
191	10/1/2005	9/30/2017	Phthalate Exposure in Pregnant Women Living in New York				
			To measure levels of phthalate metabolites in urine samples of pregnant women in New York City.				\$694,634.64
			Prior Years Funding Partner(s):				
			Columbia University				
192	8/1/2014	3/31/2016	Phthalate Exposure Testing				
	, ,	, ,	To test the prevailing hypothesis that exposure to phthalates is ubiquitous and to investigate if				\$8,029.90
			among populations with little exposure to commercial plastic and personal care products, phthalate metabolite concentration will be significantly lower than in western populations.				
			Prior Years Funding Partner(s): University of Rochester				
193	3/1/2015	ongoing	Phthalate, Sperm, and Early Life Development				4
			To investigate the association between paternal exposure to phthalates, sperm epigenetics, and reproductive health.				\$35,727.50
			Prior Years Funding Partner(s):				
			University of Massachusetts Amherst				
194	11/1/2015	6/30/2016	Phthalates and Autism Spectrum Disorders Risk				
			To evaluate whether gestational exposure to phthalates is associated with an increased risk of autism spectrum disorders.	University of California, Davis	\$102,687.00		\$102,687.00
195	5/1/2015	3/31/2018	Phthalates and Breast Cancer Risk				
	J, -, 1010	-,,20	To evaluate whether exposure to phthalates is associated with breast cancer risk in a nested case-				\$595,200.00
			control study within the Women's Health Initiative (WHI).				
			Prior Years Funding Partner(s):				
			University of Massachusetts Amherst				
				1		D. S. J.	1442246

CDC Foundation Active Programs

(October 1, 2015 -	September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(0	During CDC Fiscal Year 2016)		(All Years)
196	6/1/2016	12/31/2018	Phthalates and Diabetes Risk in Women				
			To investigate the potential association between phthalates and increased glucose dysregulation during pregnancy and postpartum period.	Harvard University	\$222,927.48		\$222,927.48
197	12/1/2014	2/14/2017	Piloting the Cardiff Model for Violence Prevention				
			To facilitate implementation of the Cardiff Model for Violence Prevention in two sites in the United States-Philadelphia, PA, and metropolitan Atlanta, GA. The purpose of the pilot is to document the strengths, challenges and costs of the program and to determine technical needs. The prevention strategies implemented in the pilot will help guide future evaluation research and implementation of the model in the United States. Prior Years Funding Partner(s): Robert Wood Johnson Foundation				\$1,100,000.00
198	1/1/2016	10/31/2016	Places and Spaces: Mapping Science				
			To present a temporary exhibition at the David J. Sencer CDC Museum that includes state-of-the-art visualization of scientific data. This exhibit will demonstrate how data visualization is linked to public health and the work of CDC.	Thomson Reuters		\$64,190.00	\$64,190.00
199	7/1/2012	12/31/2016	Planes, Trains and Auto-mobility				
			To increase walking in the Atlanta Hartsfield-Jackson International Airport using motivational signage to encourage passengers to walk from the terminal to their concourse rather than ride the airport train. Prior Years Funding Partner(s): The Kresge Foundation				\$500,000.00
200	5/1/2014	11/30/2016	Pneumococcal Disease in Qatar				
			To evaluate the impact of Pneumococcal Conjugate Vaccine (PCV-13) on vaccine and non-vaccine serotypes causing both invasive and non-invasive diseases in Qatar. The study also assesses the overall prevalence and serotype distribution of S.pneumoniae nasopharyngeal carriage in both healthy and sick children below five years of age over a three-year period. Prior Years Funding Partner(s): Hamad Medical Corporation				\$184,514.00
i						Revised: 1	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description Prior Years Funding Partner(s):				Funding
					(During CDC Fiscal Year 2016)		(All Years)
201	2/1/2012	11/30/2016	Pneumococcal Evolution and Vaccine Effectiveness To help CDC contribute to research about genetic changes in pneumococcal bacteria that impact	Emory University	\$31,300.00		\$218,600.00
			the effectiveness of vaccination in developing countries. CDC will provide isolates from their	Linory Offiversity	\$31,300.00		3218,000.00
			Global Pneumococcal Strain Bank, sequence isolates from the Active Bacterial Core surveillance				
			collaboration, and provide expert guidance on analysis and interpretation of the data.				
			Prior Years Funding Partner(s):				
			Emory University				
202	7/1/2010	12/31/2015	Pneumonia Etiology Research for Child Health (PERCH)				
			To establish a case control study of severe acute lower respiratory infections in children under age five in Thailand to determine the etiology and risk factors associated with pneumonia.	Johns Hopkins University	\$112,200.00		\$3,466,262.00
			inve in Thanana to determine the etiology and fisk factors associated with phedinolia.				
			Prior Years Funding Partner(s):				
			Johns Hopkins University				
203	7/1/2012	6/30/2016	Point-of-Care Diagnostics for Norovirus				
	,, -	-,,	To help CDC collaborate in a larger norovirus study by developing glycan-based assays to evaluate	Georgia State University	\$92,038.00		\$221,597.00
			a panel of different synthetic glycans as well as naïve norovirus stool strains.				
			Prior Years Funding Partner(s):				
			Georgia State University				
204	11/15/2010	6/30/2016	Polio Antivirals and Strain-specific Immunity				
			To accelerate development of polio antiviral compounds in support of the Polio Antivirals Initiative				\$485,563.00
			and to support studies of strain-specific immunity to polio genotypes currently circulating in India.				
			Prior Years Funding Partner(s):				
			Bill & Melinda Gates Foundation				
205	12/1/2010	12/31/2016	Positive Parenting Program				
			To help CDC's Division of Violence Prevention launch the Positive Parenting Program (Triple P)				\$1,495,000.00
			model through partnerships Federally Qualified Health Centers and local public health agencies.	I			

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					During CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): Doris Duke Charitable Foundation				
206	11/1/2015	11/30/2016	Preconception Health Mobile Application				
			To develop a preconception health mobile application that will serve as one of the intervention components of the national "Show Your Love" campaign developed by the Preconception Health and Health Care Initiative. The campaign is designed to improve the health of women and babies by promoting preconception health and healthcare.	Anthem, Inc.	\$100,000.00		\$100,000.00
207	3/1/2013	3/31/2016	Predictors of Mammary Gland Development				
			To assess the relation between putative early markers of breast cancer risk and exposure to endocrine-disrupting chemicals (EDCs), specifically phenols, such as bisphenol A (BPA), and phthalates in urinary concentrations of select phenols and phthalate metabolites in a cohort of Chilean girls. Prior Years Funding Partner(s): Harvard University				\$91,792.00
208	3/1/2015	12/31/2016	Pregnancy and Endocrine Disruptors				
			To assess the feasibility of collecting urine and blood specimens from women who enroll in the Boston University PREgnancy Study Online program and to characterize the distribution of urinary bisphenol A (BPA) and phthalate-metabolites and serum-perfluorinated chemicals in collected urine and blood specimens. Prior Years Funding Partner(s): Boston University	Boston University	32,346.06		\$52,620.82
209	7/1/2010	12/31/2016	Pregnancy and Phthalates Exposure				
			To measure phthalate levels and evaluate their association with potential birth outcomes in a population of pregnant women living in Puerto Rico. Prior Years Funding Partner(s): University of Michigan				\$176,006.04
1						Revised: 1	.1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
210	11/1/2011	ongoing	Prenatal Exposure to Infections				
			Lab analyses for prenatal exposure to infections and epilepsy in childhood.				\$48,079.00
			Prior Years Funding Partner(s):				
			Aahus University				
211	9/1/2013	3/31/2016	Prenatal Exposure to Persistent Organic Pollutants				
			To measure persistent organic pollutants (POPs) and heavy metal concentrations in women in the third trimester of their pregnancy as proxy indicators of fetus exposure in the same period of time. Prior Years Funding Partner(s):				\$29,741.50
			Instituto Nacional de Salud Publica				
212	3/1/2015	12/31/2016	Prenatal Pyrethroid and Toddler Brain Development				
			To study the association between exposure to pyrethroids during pregnancy and children's neurodevelopment at age three.	Columbia University		\$476.27	\$46,449.58
			Prior Years Funding Partner(s):				
			Columbia University				
213	8/1/2002	ongoing	Prevent Antimicrobial Resistance in Healthcare Settings Campaign				
			To develop a series of health communications aimed at increasing awareness among physicians of CDC's goals of preventing the spread of antimicrobial resistance. The goal of this initiative is to develop an integrated program to prevent emergence and spread of antimicrobial-resistant infections among patients in healthcare settings. Prior Years Funding Partner(s): BD Cubist Pharmaceuticals, Inc. (now Merck) Kimberly-Clark USA Merck Sharp & Dohme Corp.				\$597,129.00
			Ortho-McNeil Pharmaceutical, Inc.				
			Premier, Inc.				
				1			1

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(During CDC Fiscal Year 2016)		(All Years)
			University of Alabama at Birmingham Vermont Oxford Network, Inc. Wellpoint Foundation				
214	6/1/2009	6/30/2016	Preventing Infections in Cancer Patients				
			To develop a comprehensive campaign focusing on preventing infections in cancer patients by targeting patients, their families, and their providers to reduce their risk of infection in multiple settings (outpatient office, hospital, and home). Prior Years Funding Partner(s): Amgen Inc.	WebMD, LLC		\$37,480.00	\$2,673,993.00
215	10/1/2015	4/30/2017	Preventing Maternal Deaths in Tanzania				
			To focus on improving family planning and maternal health in Tanzania's Kigoma region in the third phase of this project involving CDC, the World Lung Foundation and Engender Health.	Bloomberg Philanthropies	\$1,576,000.00		\$1,576,000.00
216	7/1/2012	ongoing	Preventing Mother-to-Child Transmission of HIV and HBV				
			To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mother-to-child transmission of HIV and HBV in co-infected mothers. Prior Years Funding Partner(s): Gilead Sciences, Inc.				\$362,800.00
217	11/1/2011	8/31/2016	Primate Retroviral Transmission				
			To track the transmission of blood-borne microbes between non-human primates and domestic animals living near Kibale National Park, Uganda. Prior Years Funding Partner(s): University of Wisconsin	University of Wisconsin		\$11,850.00	\$68,385.15
1						Revised	: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	Ouring CDC Fiscal Year 2016)		(All Years)
218	11/1/2011	5/31/2016	Production of Rabies Virus Antigens in Rice				ά 7 Γ. Γ. 40. 00
			To help CDC collaborate in the development of a new rice-based rabies vaccine that has the potential to be safer and less expensive than current oral rabies vaccines.				\$75,549.00
			Prior Years Funding Partner(s):				
			Ventria Bioscience				
219	9/1/2015	8/31/2018	Protective Immunity to Norovirus in Indian Cohort				
			To establish the role of norovirus as a cause of diarrheal disease and to understand the development of protective immunity in a birth cohort in India.				\$154,000.00
			Prior Years Funding Partner(s): Christian Medical College, Vellore				
220	11/1/2010	12/31/2015	Rabies Prevention in Developing Countries				
			To support CDC's work with partners in the Philippines and Central Africa to prevent and reduce rabies transmission between animals and humans through increased vaccination and education.				\$3,617.82
			Prior Years Funding Partner(s):				
			Various Individual and Organizational Contributors				
221	5/1/2015	12/31/2016	Rapid Diagnostic Tests for Malaria Elimination				
			To support the development of improved rapid diagnostic tests for malaria elimination making available panels of cultured parasites for product development and validation.				\$29,803.60
			Prior Years Funding Partner(s): Foundation for Innovative New Diagnostics				
222	10/1/2007	6/30/2016	Reducing HIV Acquisition Through PrEP - Uganda				
			To assess, through clinical trials in Uganda, the safety and efficacy of pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine/tenofovir in reducing HIV acquisition.				\$4,368,775.60
			Prior Years Funding Partner(s):				
			University of Washington				
I				I		Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
223	8/1/2011	9/30/2017	Reproductive Health Issues and Exposures to PBBs				
			To measure polybrominated biphenyls (PBBs) and determine the extent of endocrine disruption resulting from exposure to these compounds.				\$170,422.36
			Prior Years Funding Partner(s):				
			Emory University				
224	1/4/2011	2/11/2016	Research Fellowships for FETP Graduates				
	-, -,	-,,	To help CDC provide technical assistance and expertise to support the African Programme for				\$45,707.00
			Advanced Research Epidemiology Training, a program that provides fellowships and research grants to graduates of Field Epidemiology Training Programs (FETPs).				
			Prior Years Funding Partner(s):				
			Bernhard Nocht Institute for Tropical Medicine				
225	12/1/2012	12/31/2016	Rift Valley Fever Virus Vaccination Development				
			To assist in the development of novel vaccines and comprehensive strategies for the prevention of Rift Valley Fever virus in both livestock and humans using recombinant proteins and 96-well ELISA or Luminex platforms to detect anti-NP, anti-NSs, or anti-NSm antibodies. Prior Years Funding Partner(s): Texas A&M University				\$136,472.00
226	10/1/2010	9/30/2016	Road Traffic Prevention and Control in India				
220	10/1/2010	9/30/2010	To work closely with partners in India to develop, implement, evaluate and disseminate evidence-based interventions to address the critical issue of occupational and non-occupational road safety and trauma care and to promote road traffic injury prevention. Prior Years Funding Partner(s): Conrad N. Hilton Foundation				\$750,000.00
227	3/1/2016	12/31/2017	Role of Phthalates and Phenols in Autism Risk				
			To investigate the potential association between phthalates and environmental phenols as a risk factor for autism.	Drexel University	\$146,516.52	Revised: 1	\$146,516.52 1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	During CDC Fiscal Year 2016)		(All Years)
228	9/1/2015	12/31/2017	Role of Phthalates and Vitamin E in Diabetes Risk				
	.,,	, , ,	To investigate the potential role of phthalates and vitamin E in risk of diabetes.				\$14,291.00
			Prior Years Funding Partner(s): University of North Carolina at Chapel Hill				
229	9/1/2007	ongoing	Rotavirus Breast Milk Analysis				
230	8/1/2013	7/31/2017	To collect breast milk from mothers in developing countries with infants less than 6 months of age in order to examine levels of antibody response to rotavirus and compare the inhibitory effect of maternal antibody on vaccine strains. Prior Years Funding Partner(s): Centers for Disease Control and Prevention Emory University GlaxoSmithKline Biologicals National Science and Technology Council University of North Carolina at Chapel Hill Wuhan Institute of Biological Products Rotavirus Intussusception Study in South Africa	Emory University GlaxoSmithKline Biologicals		\$8,821.80 \$16,329.20	\$1,248,411.40
			To initiate a network of South African hospitals to conduct intussusception surveillance and apply the resource-efficient and scientifically sound case-series analysis to generate vital evidence for monitoring the safety of rotavirus vaccine use. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation		\$386,337.00	\$2,382,180.00
231	9/1/2013	2/28/2016	Rotavirus Journal Supplement on Vaccines in India				40=
			To collaborate with local experts and institutions in India, including the Ministry of Health and Family Welfare (MOHFW) and the Indian Council of Medical Research (ICMR), on the production of a journal supplement focused on rotavirus diarrhea and vaccine in India. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation				\$275,433.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
					(During CDC Fiscal Year 2016)		(All Years)
232	10/1/2007	12/31/2016	Rotavirus Surveillance				
			To allow countries, primarily in Asia and Africa, to continue rotavirus surveillance activities in anticipation of the introduction of the rotavirus vaccine.				\$252,232.00
			Prior Years Funding Partner(s):				
			GlaxoSmithKline Biologicals				
			Merck Sharp & Dohme Corp.				
233	10/1/2012	11/30/2017	Rotavirus Surveillance in Ghana and Rwanda				
			To determine, following the introduction of the rotavirus vaccine in Ghana and Rwanda, the				\$1,081,502.00
			impact of the vaccine on rotavirus cases and on diarrhea morbidity from all causes.				
			Prior Years Funding Partner(s):				
			PATH				
234	8/1/2011	9/30/2016	Rotavirus Vaccine in Developing Countries				
			To develop evidence for improving the performance of live, attenuated, orally delivered rotavirus vaccines in infants in the developing world.				\$1,268,930.00
			Prior Years Funding Partner(s):				
			PATH				
235	12/1/2012	12/31/2017	Rotavirus Vaccine Intussusception Surveillance				
			To develop a network of intussusception surveillance in 6-7 countries planning to adopt rotavirus vaccination in 2012-2014. A key issue for the wide, sustained use of rotavirus vaccines is the demonstration of safety, especially with regard to intussusception, a serious but uncommon intestinal blockage.				\$1,822,803.00
			Drier Veers Funding Partner(s)				
			Prior Years Funding Partner(s): PATH				
			FAIII				
				'		Revised: 1	1142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
			Prior rears runding Partner(s).	([During CDC Fiscal Year 2016)		(All Years)
236	6/1/2012	ongoing	Safe Delivery for Mothers in Western Kenya				
			To purchase and provide delivery kits, safe blood supply and motorcycle transportation to facilities for expecting mothers in labor to women in Nyanza Province, living within KEMRI/CDC's Health and Demographic Surveillance Systems (HDSS) study area.				\$2,380.00
			Prior Years Funding Partner(s):				
			Various Individual and Organizational Contributors				
237	10/1/2008	ongoing	Safe Injection Practices Coalition				
			To promote safe injection practices in all U.S. healthcare settings, the Safe Injection Practices Coalition is a partnership of healthcare-related organizations, patient advocacy organizations, industry partners and other public health partners, led by CDC. The Coalition has developed the One & Only Campaign-a public health education and awareness campaign-aimed at both healthcare providers and patients to advance and promote safe injection practices. Prior Years Funding Partner(s): Accreditation Association for Ambulatory Health Care, Inc. Ambulatory Surgery Foundation American Association of Nurse Anesthetists Association for Professionals in Infection Control and Epidemiology, Inc. BD Eli Lilly and Company Hospira, Inc. Mallinckrodt Group Inc. MEDRAD, INC. Nebraska Medical Association Nevada State Medical Association				\$957,177.68
ľ			Novo Nordisk Inc. Premier, Inc.				
238	9/1/2009	6/30/2016	Safe Injection Practices Services				
			To prevent the transmission of hepatitis C and other diseases by educating healthcare professionals and health consumers about safe injection practices.				\$1,899,999.70
						Revised: 1	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(C	Ouring CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): Centers for Disease Control and Prevention				
239	7/1/2014	5/31/2017	Screening of Congenital Adrenal Hyperplasia				
			To determine the impact of molecular testing on newborn screening for Congenital Adrenal Hyperplasia (CAH). The goal of the project is to improve clinical outcomes by early detection and treatment of infants affected by CAH and to reduce the burden of false positives on families and providers. Prior Years Funding Partner(s): University of Minnesota				\$107,598.00
240	3/1/2016	6/30/2019	Semi-Volatile Organics Exposure in Children				
			To investigate the potential association between home exposure in children (ages 2-6) to semivolatile organics and obesity.	Duke University	\$100,000.00		\$100,000.00
241	4/1/2016	6/30/2017	Sixth International Calicivirus Conference				
			To support the travel, accommodation and participation of researchers from low- income and middle-income countries to attend the 2016 International Calicivirus Conference.	Bill & Melinda Gates Foundation		\$80,000.00	\$80,000.00
242	11/1/2011	ongoing	Smallpox Zero Reminiscences Project				
			To help the Edward Jenner Museum in Berkeley, UK, collaborate with the David J. Sencer CDC Museum to record smallpox eradication experiences and collect memorabilia worldwide. Prior Years Funding Partner(s): Conrad N. Hilton Foundation Marguerite Casey Foundation				\$55,000.00
243	4/1/2010	1/31/2016	Social Determinants of Health				¢350.000.00
			To provide resources to translate academic literature on social and economic causes of inequities in health and safety into accessible formats for use by health practitioners, communities and the broader public; develop a conceptual framework and methods for collecting, analyzing and making use of data on the structures of decision making that generate health inequities in local jurisdictions; and produce a manual that can be used to guide the development and evaluation of interventions to address inequities in health and safety.				\$250,000.00

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner Committed Award Cash (During CDC Fiscal Year 2016)	Cumulative Funding (All Years)
			Prior Years Funding Partner(s): W.K. Kellogg Foundation		
244	10/1/2012	9/30/2016	Stanford Asthma Study To determine biological mechanisms involved in Treg impairment resulting from PAH exposure and their effects on asthma. Prior Years Funding Partner(s): Lucile Packard Children's Hospital at Stanford		\$107,552.00
245	12/1/2012	12/31/2016	Strategic Planning to Enhance EIS Alumni Association Operations To strengthen the Epidemic Intelligence Service (EIS) Alumni Association (EISAA) and support the EIS Program. The EISAA proposes to fortify the Alumni Association to ensure its robust viability, vision, organization, and resources are oriented to support the alumni network and the EIS Program growth at CDC. A new, interactive EISAA website and heightened EIS recruitment are in development. Prior Years Funding Partner(s): de Beaumont Foundation		\$24,960.00
246	10/1/2008	12/30/2016	Strengthening Disease Surveillance and Response in Central Africa To strengthen disease surveillance and response programs in select Central African countries. Prior Years Funding Partner(s): Bill & Melinda Gates Foundation		\$25,495,069.00
247	8/1/2014	6/30/2017	Strengthening Disease Surveillance in West Africa To provide applied epidemiology training to public health officials from the ministries of health of the French-speaking member states that constitute the Economic Community of West African States. Prior Years Funding Partner(s): West African Health Organisation	Revised: 1114	\$2,541,437.00

CDC Foundation Active Programs

			(October 1, 2015 - September 30, 2016)
CDCF Start	Projected	Program	Funding Partner

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	ring CDC Fiscal Year 2016)		(All Years)
				1			
248	9/1/2015	9/30/2020	Strengthening Global Emergency Management				
			To fortify elements critical to global health security - public health infrastructure and country capacity - to ensure rapid detection and response of public health threats in the West Africa region. Prior Years Funding Partner(s): Centers for Disease Control and Prevention	Centers for Disease Control and Prevention	\$1,168,600.00		\$1,568,600.00
249	7/1/2014	8/15/2017	Strengthening Laboratory Quality in Kazakhstan				
			To assist the Ministry of Health of the Republic of Kazakhstan in developing quality control mechanisms and a state-of-the-art laboratory quality management system model. The project will strengthen laboratory quality assurance systems and help set up a National Reference Laboratory and four expert laboratories to serve as methodological and educational centers for laboratory networks and build capacity for laboratory staff, managers and decision makers. Prior Years Funding Partner(s): International Bank for Reconstruction and Development	International Bank for Reconstruction and Development (Ministry of Public Health of the Republic of Kazakhstan)		\$520,000.00	\$1,300,000.00
250	9/1/2015	9/30/2016	Strengthening the EIS Alumni Association				
			To strengthen the Epidemic Intelligence Service (EIS) Alumni Association (EISAA) and support the EIS Program. In an era of challenging public health priorities and fewer resources, a growing concern of CDC and the EISAA is ensuring program support in areas in which CDC and government financial and human resources are reduced. The EISAA proposes to strengthen the Alumni Association to ensure its vision, organization, and resources are oriented to support the alumni network and the EIS Program at CDC. Prior Years Funding Partner(s): de Beaumont Foundation				\$62,400.00
251	12/1/2004	ongoing	Study of Blood Inhibitors in Hemophilia Patients				
			To monitor hemophilia patients for the development of inhibitors and establish a surveillance system to collect and analyze a uniform set of clinical data. Prior Years Funding Partner(s): Baxter International Inc.			Revis	\$6,830,000.00 ed: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	uring CDC Fiscal Year 2016)		(All Years)
			Wyeth Pharmaceuticals				
252	3/1/2016	11/30/2016	Study of Dapivirine Gel Administered Rectally				
			To study the effectiveness of dapivirine gel exposure intended to prevent HIV transmission.	Magee-Womens Research Institute and Foundation	\$142,496.00		\$142,496.00
253	12/1/2015	12/31/2018	Substance Use and HIV Prevention Education				
			To provide substance use and HIV prevention education, access to health services, safe and supportive environments and monitoring and evaluation for high-risk communities in Kentucky, Ohio and Indiana.	Conrad N. Hilton Foundation	\$1,500,000.00		\$1,500,000.00
254	2/1/2015	12/31/2017	Supporting Water, Sanitation & Hygiene in Mali				
			To provide both rapid and sustainable access to water to an estimated 66,000 people in healthcare facilities in marginalized, rural, trachoma-endemic communities in Mali. Prior Years Funding Partner(s): WaterAid America				\$92,038.07
255	7/1/2013	ongoing	Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study				
			To learn lessons about how best to incorporate the delivery of daily oral pre-exposure prophylaxis (PrEP) into the services provided by health centers serving sexually active adults at high risk of acquiring HIV infection. The pilot study will initiate data collection at federally-qualified health centers (FQHCs) or look-alikes in four U.S. cities. Prior Years Funding Partner(s): Gilead Sciences, Inc.				\$4,050,259.00
256	8/1/2010	ongoing	Synthesis of XMRV Peptides				
			To develop a mass spectrometry method that can be used to identify and quantify a novel protein produced by the prostate-cancer-associated retrovirus XMRV in patient samples. Prior Years Funding Partner(s): Edinburgh Napier University Emory University Global Blood Therapeutics, Inc. Lypro Biosciences, Inc.				\$27,184.32
ı						Revised:	11142016

CDC Foundation Active Programs

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description				Funding
			Prior Years Funding Partner(s):				
				(Di	uring CDC Fiscal Year 2016)		(All Years)
			The Children's Hospital of Philadelphia				
			University of Louisville School of Dentistry				
			University of Maryland, Baltimore				
256	10/1/2015	10/30/2016	Tackling Hunger to Improve Health in Americans				
			To identify and disseminate effective strategies to address the cycle of food insecurity and its	AARP Foundation	\$458,464.00		\$609,949.00
			relationship to acute medical events in people with chronic diseases.	Toledo Community Foundation, Inc. (ProMedica)		\$151,485.00	
				(Prolivieulca)			
257	5/1/2014	9/30/2016	TB Clinical Research Database & Drug Monitoring				
			To abstract data from medical records of tuberculosis patients to study modeling the				\$46,640.00
			pharmacokinetics of second-line anti-tuberculosis drugs.				
			Prior Years Funding Partner(s):				
			University of Florida				
258	3/1/2015	5/1/2017	Temporal Variability-Urine Phenol During Pregnancy				
250	3/1/2013	5/1/201/	To study the temporal variability of phenol urinary concentrations during pregnancy, focusing on				\$55,188.36
			the between-day and between-trimester variability. The study will identify the efficiency of				755,100.50
			within-subject pooling of biospecimens to characterize the mean urinary levels of phenols during				
			pregnancy.				
			Prior Years Funding Partner(s):				
			INSERM				
259	7/1/2012	ongoing	Testing of Sexual Identity Questions by CDC's National Center for Health Statistics				
	., _,		To develop and field test questions on sexual identity for inclusion in the National Health				\$200,000.00
			Interview Study.				
			Prior Years Funding Partner(s):				
			Gill Foundation				
260	1/1/2007	6/30/2016	Testosterone Measurement Harmonization				
			To improve and standardize testosterone measurements to help provide better medical care to				\$3,068,178.50
			people with impaired androgen levels and people receiving androgen therapy.				
				•		Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	uring CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): AB SCIEX LLC Abbott Laboratories (formerly Solvay) Roche Diagnostics Corporation				
261	7/1/2002	ongoing	The Bob Keegan Polio Eradication Heroes Fund				
			The Polio Eradication Heroes Fund recognizes health workers and volunteers who have incurred serious injury or lost their lives as a direct consequence of their participation in polio eradication activities. The families of the workers, who have been the victims of automobile crashes, military conflicts and other life-threatening events, receive a certificate recognizing the victim's heroic commitment to polio eradication and a cash tribute. Prior Years Funding Partner(s): Environmental Systems Research Institute Rotary International Various Individual and Organizational Contributors	Various Individual and Organizational Contributors		\$29,427.00	\$214,419.15
262	2/1/2015	12/31/2017	The Microbiome in Pregnancy and Infancy				
			To characterize environmental exposures experienced by pregnant women and their infant children and their association with the developing human intestinal microbiome. Concentrations of triclosan and parabens will be measured in urines collected from pregnant women who participated in the Lifecodes study and their infants. Prior Years Funding Partner(s): Harvard University				\$10,951.20
263	5/1/2014	4/30/2017	Thyroid Cancer Risk Study				
			To investigate the relationship between polyhalogenated aromatic hydrocarbons (PHAHs) and thyroid hormones and the risk of thyroid cancer. This study will investigate whether the risk of thyroid cancer and thyroid hormone disruption associated with environmental exposure to PHAHs varies by genetic polymorphisms in major genes coding for enzymes involved in the regulation, metabolism or functional activities of PHAHs and endogenous thyroid hormones. Prior Years Funding Partner(s): Yale University				\$477,491.20
						Revised:	11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(1	During CDC Fiscal Year 2016)		(All Years)
							1
264	2/1/2010	12/31/2016	Time to Conceive and Biomarkers of Infertility				
			To assess the reproductive potential of women exposed to occupational hazards.				\$10,532.19
			Prior Years Funding Partner(s):				
			University of North Carolina at Chapel Hill				
265	8/1/2015	12/31/2019	Tobacco Constituents in Female Menthol Smokers				
			To measure tobacco exposure biomarkers in female menthol smokers and to examine the potential impact of regulatory actions.				\$305,875.40
			Prior Years Funding Partner(s): University of Connecticut				
266	8/1/2014	7/30/2018	Tobacco Control Surveillance in Africa				
			To create a standard surveillance system to monitor tobacco use and key tobacco control measures across Sub-Saharan Africa. The data will enhance and strengthen tobacco control research and policy capacity in low- and middle-income countries, where the emergence of a tobacco epidemic is a concern.				\$4,597,068.00
			Prior Years Funding Partner(s):				
			Bill & Melinda Gates Foundation				
267	12/1/2009	9/30/2016	Together for Girls				
			To enable CDC to work with individual countries and regions to quantify the problem of sexual violence against girls and subsequently develop evidence-based policies and programs to protect children and prevent violence.	Various Individual and Organizational Contributors		\$10,345.62	\$1,758,004.07
			Prior Years Funding Partner(s):				
			BD				
			Henry Schein Cares Foundation				
			Nduna Foundation				
			United Nations Development Programme (UNFPA, United Nations Population Fund)	I			
						Revised:	11142016

CDC Foundation Active Programs (October 1, 2015 - September 30, 2016)

	CDCF Start Date	Projected End Date	Program Program Description	Funding Partner	Committed Award	Cash	Cumulative Funding
	Date	Liid Date	Prior Years Funding Partner(s):				runung
							town >
				(C	During CDC Fiscal Year 2016)		(All Years)
268	10/1/2013	ongoing	Toxicants and Infant Male Reproductive Systems				
			To assess the effects of prenatal phthalate exposure on the developing male reproductive system.				\$83,856.00
			Anogenital distance will be used as a marker of exposure to reproductive toxicants and their				
			effects. CDC's Organic Analytical Toxicology Branch will provide biomonitoring data on phthalate metabolites in 786 urine samples collected prenatally from mothers who participated in the Infant				
			Development and the Environment (TIDES) Study.				
			bevelopment and the Environment (Tibes) stady.				
			Prior Years Funding Partner(s):				
			Mount Sinai School of Medicine				
269	6/1/2007	9/30/2016	Trachoma and Lymphatic Filariasis in Mali				
			To research programs that will contribute to the development of a fully integrated, sustainable				\$1,198,756.60
			and scalable comprehensive control program for trachoma and lymphatic filariasis in Mali.				
			Prior Years Funding Partner(s):				
			International Trachoma Initiative				
			Task Force for Global Health				
			Tusk Torce for Global Treater				
270	6/14/2007	6/30/2016	Treatment of TB with Priftin® (rifapentine)				
			To continue the research and development of the drug Priftin® (rifapentine) and to investigate its				\$2,933,292.00
			role in the treatment of active tuberculosis (TB) disease and latent TB infection.				
			Drien Vegra Funding Doubnorfe)				
			Prior Years Funding Partner(s): Sanofi-Aventis				
			Sanofi Foundation for North America				
271	4/1/2016	2/28/2017	Typhoid Vaccine Protocol Development				
		· ·	To develop a standardized protocol that developing country vaccine manufacturers may use for	Bill & Melinda Gates Foundation		\$50,025.00	\$50,025.00
			evaluating Vi enzyme-linked immunosorbent assays and reference standards to support product				
			registration.				
272	6/1/2015	12/31/2016	Understanding Antibiotic Use Data				
	0/ 1/ 2015	12/31/2010		The Pew Charitable Trusts	¢200 F22 00		ĆE72 022 00
			To gain a comprehensive understanding of antibiotic use in inpatient and outpatient healthcare settings in the United States.	Various Individual and	\$298,532.00	\$500.00	\$572,932.00
			settings in the Officea States.	Organizational Contributors		00.000	1
				To Samzational Continuators			1

Revised: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(Du	uring CDC Fiscal Year 2016)		(All Years)
			Prior Years Funding Partner(s): The Pew Charitable Trusts Various Individual and Organizational Contributors				
273	3/1/2013	12/31/2017	Vaccine Effectiveness in HIV-Infected Children				
			To estimate the effectiveness of two or more doses of 13-valent pneumococcal conjugate vaccine (PCV-13) against laboratory-confirmed vaccine-serotype invasive pneumococcal disease (IPD) (13 serotypes in the vaccine) among HIV-infected and HIV-uninfected children eligible to receive vaccination through the routine vaccination program in South Africa, compared to no vaccination. Prior Years Funding Partner(s): PATH				\$214,897.00
274	12/1/2012	10/31/2017	Vaccine Induced Immune Responses to Plasmodial Antigens				
			To support an immunization and chade Beaumontllenge trial of CDC's P. falciparum chimeric MSP1/8 vaccine in nonhuman primates. The specific model will involve studies in the monkey species Aotus nancymaae using the P. falciparum FVO strain. Prior Years Funding Partner(s): Drexel University				\$91,951.00
275	2/1/2015	12/31/2017	Vaccine Research and Surveillance				
			To conduct vaccine research and surveillance with several countries to determine the burden of vaccine preventable diseases, including meningitis, pneumonia, intussusception and rubella. The partnership will enhance the quality of disease and coverage data and assess vaccine impact. Prior Years Funding Partner(s): Global Alliance for Vaccines and Immunization	Global Alliance for Vaccines and Immunization	\$4,204,619.00		\$7,719,125.00
276	6/1/2016	5/30/2017	Vector Stock and Reagent Repository for Research				
			To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) Program.	American Type Culture Collection	\$337,009.17	Revised: 1	\$337,009.17 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(D	uring CDC Fiscal Year 2016)		(All Years)
				,-			
277	12/1/2012	2/11/2016	Vertebral Fracture Assessment in NHANES				
			To add vertebral fracture assessment (VFA) to the 2013-2014 National Health and Nutrition Examination Survey (NHANES) using lateral spine dual-energy X-ray absorptiometry (DXA) scans, anterior-posterior (AP) spine and femur DXA scans for bone mineral density (BMD) and a Fracture Risk Assessment Tool (FRAX) which includes questions related to osteoporosis and fractures. Prior Years Funding Partner(s): Eli Lilly and Company				\$897,132.00
278	8/1/2016	8/30/2017	Violence Against Children Survey for Domestic Use				
			To assess the possibility of adapting the global Violence Against Children Survey for use in the United States and identifying funding partners.	Robert Wood Johnson Foundation	\$52,085.00		\$52,085.00
279	10/1/2009	ongoing	Viral Hepatitis Action Coalition (VHAC)				
			To provide an overall framework for organizations concerned with viral hepatitis to support high priority research, education and program evaluation projects initiated by CDC's Division of Viral Hepatitis.	Abbott Laboratories AbbVie Inc.		\$25,000.00 \$50,000.00	\$3,284,106.00
			Prior Years Funding Partner(s):	Bristol-Myers Squibb Company		\$50,000.00	
			Abbott Laboratories	Johnson & Johnson (Janssen)		\$50,000.00	
			AbbVie Inc.	Merck & Co.		\$25,000.00	
			Alere North America, Inc.	OraSure Technologies, Inc.		\$50,000.00	
			American Association For The Study of Liver Diseases	Quest Diagnostics		\$50,000.00	
			Bayer Corporation	Siemens USA		\$50,000.00	
			Boehringer Ingelheim USA Corporation				
			Bristol-Myers Squibb Company				
			Gen-Probe, Incorporated				
			Genentech, Inc.				
			Gilead Sciences, Inc.				
			GlaxoSmithKline Biologicals				
			Janssen Therapeutics				
			Johnson & Johnson Kadmon Pharmaceuticals, LLC				
			Merck & Co., Inc.				
			merek & co., me.	1		Revised:	11142016

CDC Foundation Active Programs

	CDCF Start	Projected	Program	Funding Partner	Committed Award	Cash	Cumulative
	Date	End Date	Program Description				Funding
			Prior Years Funding Partner(s):				
				([During CDC Fiscal Year 2016)		(All Years)
			Mount Sinai School of Medicine				
			Onyx Pharmaceuticals, Inc.				
			OraSure Technologies, Inc.				
			Quest Diagnostics				
			Schering Plough Corporation				
			Siemens USA				
			University of the Sciences				
			Vertex Pharmaceuticals, Incorporated				
280	8/1/2014	7/30/2017	Viral Hepatitis in Resource-Limited Countries				
			To develop an action plan and framework to guide the treatment and testing of viral hepatitis in				\$4,950,000.00
			resource-limited countries. CDC's Division of Viral Hepatitis and the World Health Organization will work directly with ministries of health in key countries to expand capacity and establish and				
			implement effective strategies around viral hepatitis control.				
			Prior Years Funding Partner(s):				
			Gilead Sciences, Inc.				
281	1/1/2010	ongoing	Viral Variants for Rabies Research and Interventions				
	-/ -/	0.160.116	To generate infectious rabies virus variants from naturally infected animals which can then be				\$92,873.00
			used in rabies research designed to improve disease prevention after exposure as well as				
			intervention after disease onset.				
			Prior Years Funding Partner(s):				
			Ark Sciences, Inc.				
			Global Alliance for Rabies Control				
			The University of Texas Medical Branch				
282	10/1/2010	ongoing	Watching Hands: Artists Respond to Keeping Well				
			To help CDC's Global Health Odyssey Museum organize an art exhibit that explores the messages of hand hygiene as interpreted by contemporary artists.				\$106,690.00
			Prior Years Funding Partner(s):				
			Georgia-Pacific Corporation	I			I
						Revised	: 11142016

CDC Foundation Active Programs

	CDCF Start Date	Projected End Date	Program Program Description Prior Years Funding Partner(s):	Funding Partner	Committed Award	Cash	Cumulative Funding
				(C	During CDC Fiscal Year 2016)		(All Years)
					<i>,</i>		1
283	12/1/2014	7/31/2016	Water Quality Testing in Low-Resource Settings				
			To develop the evidence base for use of the Compartment Bag Test, a portable water quality test that determines if drinking water contains E. coli bacteria and poses a health risk. This study will provide international public health organizations scientifically-backed guidance on use of the test in low-resource settings and during emergency response.	Conrad N. Hilton Foundation	\$100,000.00		\$100,000.00
284	2/1/2015	6/30/2016	Word-of-Mouth Travel Health Education Programs				
			To improve acceptance of pre-travel vaccines, medicines, and preventive behaviors among highrisk travelers through evaluation of the outcome of a word-of-mouth (WOM) travel health education program among Asian Indians in the New York/New Jersey/Connecticut area. Prior Years Funding Partner(s): GlaxoSmithKline Biologicals				\$240,683.00
285	3/1/2016	3/30/2017	Youth HIV/STD Prevention Campaign				
			To implement a HIV/STD prevention campaign for youth and gay, bisexual and transgender (GBT) youth.	M.A.C. AIDS Fund		\$1,000,000.00	\$1,000,000.00
286	11/1/2012	6/30/2016	Zoster Vaccine and Postherpetic Neuralgia				
			To help CDC participate in a larger research collaboration on zoster vaccine. CDC will 1) perform VZV PCR for detection of viral DNA and discrimination of vaccine strain from wild-type, 2) identify vaccine: wild-type recombinant isolates, and 3) conduct VZV Quantitative PCR on saliva specimens. Prior Years Funding Partner(s): Kaiser Permanente	Kaiser Permanente	\$16,614.00		\$139,124.00